Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 7948. Отображено 100.
08-03-2012 дата публикации

nanoparticulate compositions of poorly soluble compounds

Номер: US20120058151A1
Принадлежит: CAPSULUTION PHARMA AG

The present invention relates to a method for the production of a nanoparticulate pharmaceutical composition. The method comprises the steps of a) suspending in water a poorly soluble active ingredient without the presence of a detergent, b) mechanically treating said suspension to obtain particles comprising the active ingredient with an effective average size of less than about 5000 nm, c) contacting said active ingredient or suspension with a first polyelectrolyte during and/or before mechanically treating, d) optionally contacting said suspension with a one or more second or further polyelectrolytes during, before and/or after mechanically treating, e) optionally drying said suspension. The invention also pertains to the pharmaceutical compositions obtained by the method of the invention.

Подробнее
08-03-2012 дата публикации

Pharmaceutical formulations comprising substituted benzimidazole derivatives

Номер: US20120058194A1

Stabilized substituted benzimidazole modified release pharmaceutical formulations with at least two drug-containing fractions, wherein the release from a first fraction precedes the release from a second fraction, pharmaceutical excipients, processes for preparing the stable formulations, packaging therefor, and their use in treatment of erosive esophagitis and heartburn associated with non-erosive gastroesophageal reflux disease.

Подробнее
08-03-2012 дата публикации

Compositions and methods for elimination of gram negative bacteria

Номер: US20120058936A1

Oral drug delivery formulations which specifically administer antibacterial agents to the ileum, caecum, and/or the colon, without significant administration elsewhere in the gastrointestinal tract, are disclosed. The formulations include, as actives, a combination of a macrolide or aminoglysoside, or quinolone antibacterial and an anti-Gram-negative lipopeptide (polymyxin) antibacterial agent or other peptide antibacterials effective against Gram-negative bacteria. The formulations can be used to treat infections or unwanted colonization in the colon, and to provide effective decontamination of the colonic flora from unwanted or potentially pathogenic bacteria.

Подробнее
15-03-2012 дата публикации

Oral pharmaceutical composition for use in respiratory diseases

Номер: US20120064155A1
Принадлежит: Laboratorios Senosiain SA de CV

A modified-release oral pharmaceutical composition in capsules with microspheres contains loratadine, phenylephrine and pharmaceutically acceptable excipients. The composition has immediate bioavailability, with plasmatic concentration values within the therapeutic window with a uniform, continuous release. A method for the production of the composition and a method for treatment as a nasal decongestant and an antihistamine are included.

Подробнее
15-03-2012 дата публикации

Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs

Номер: US20120064156A1
Автор: John R. Plachetka
Принадлежит: Individual

The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.

Подробнее
03-05-2012 дата публикации

Pharmaceutical formulation containing gelling agent

Номер: US20120108622A1
Принадлежит: Purdue Pharma LP

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Подробнее
02-08-2012 дата публикации

Preparation of controlled release skeletal muscle relaxant dosage forms

Номер: US20120196028A1
Принадлежит: Aptalis Pharmatech Inc

The present invention is directed to a method of preparing an extended release pharmaceutical composition comprising cyclobenzaprine, comprising coating inert particles with a cyclobenzaprine-containing a drug layering composition to form IR beads, then coating the IR beads with an extended-release coating to form ER beads.

Подробнее
02-08-2012 дата публикации

Compositions of 5-ht3 antagonists and dopamine d2 antagonists for treatment of dopamine-associated chronic conditions

Номер: US20120196877A1
Автор: Nikhilesh N. Singh
Принадлежит: Transcept Pharmaceuticals Inc

The present invention provides novel compositions comprising a combination of a 5-HT 3 receptor antagonist and a selective dopamine D 2 receptor antagonist for the treatment of obsessive, impulsive and compulsive behavioral activities and other dopamine pathway-associated disorders or conditions. Preferably, the pharmaceutical compositions of the present invention comprise amounts of the 5-HT 3 receptor antagonist ondansetron and a selective dopamine D 2 receptor antagonist, such as risperidone or olanzapine, that are sufficient to control a subject's obsessive, impulsive and compulsive behavioral activities. Kits comprising the combination of antagonists for the treatment of addictive disorders such as alcohol dependence are also provided.

Подробнее
02-08-2012 дата публикации

Beta 2 Adrenergic Receptor Agonists Such As Terbutaline for Use in the Treatment of Nocturnal Hypoglycemia

Номер: US20120196938A1
Автор: Guy Vergnault
Принадлежит: JAGOTEC AG

The invention is concerned with methods, regimens and dosage forms employing a beta 2 adrenergic receptor agonist such as terbutaline sulphate, for treating nocturnal hypoglycaemia in human subjects whilst reducing incidence of hyperglycaemia in said subjects upon wakening.

Подробнее
16-08-2012 дата публикации

Treatment of Psoriasis Using Oral Dosage Forms of Nitrone Spin Traps

Номер: US20120207838A1
Автор: Nicholas V. Perricone
Принадлежит: Individual

Psoriasis is treated by oral administration of a pharmaceutical composition containing a nitrone spin trap such as α-phenyl t-butyl nitrone (PBN) and derivatives thereof. Preferred compositions and method of treatments further comprise at least one adjunct ingredient including fatty acid esters of ascorbic acid such as ascorbyl palmitate and ascorbyl stearate. The pharmaceutical composition can be prepared as an immediate release formulation or controlled released formulations.

Подробнее
16-08-2012 дата публикации

Floating microgranules

Номер: US20120207843A1
Принадлежит: Debregeas Et Associes Pharma SAS

A floating granule having a solid core, on which an active ingredient is supported, and a compound capable of generating a gas discharge which is constituted by an alkaline agent, characterised in that it does not comprise an acid agent that is capable of generating a gas discharge.

Подробнее
06-12-2012 дата публикации

Orally administrable pharmaceutical pellet of epidermal growth factor

Номер: US20120308661A1

The present invention comprises a pellet of epidermal growth factor and methionine or K 2 S 2 O 7 , a capsule which comprises these pellets, processes for theirs preparations and it use for the treatment of ulcerative colitis.

Подробнее
13-12-2012 дата публикации

Multiparticulate l-carnitine compositions and related methods

Номер: US20120315326A1
Автор: Noreen HASSAN, Syed Shah
Принадлежит: Hassan Noreen, Shah Syed

Enteric coated multiparticulate compositions that use a L-carnitine compound an active ingredient are disclosed. The multiparticulates have spheroidal core comprising a L-carnitine, microcrystalline cellulose, and hydroxypropyl methylcellulose; a sub-coat comprising hydroxypropyl methyl cellulose on the spheroidal core; and an enteric coat on the sub-coated spheroidal core. The average diameter of the particulates is about 0.1-3 mm. Other aspects of the invention include methods of making and methods of using the multiparticulate compositions.

Подробнее
17-01-2013 дата публикации

Multicarotenoid beadlets and related method

Номер: US20130017292A1
Принадлежит: ACCESS BUSINESS GROUP INTERNATIONAL LLC

A controlled release beadlet that sequentially releases carotenoids over time within the gastrointestinal tract of a subject, as well as a method of administering the carotenoids. The beadlet provides a specific ratio of carotenoids which release from the beadlet at preselected times during passage through the gastrointestinal tract. The method includes releasing the carotenoids in preselected ratios at specific time intervals in the gastrointestinal tract to mitigate competition between the carotenoids for their uptake, and/or to potentially maximize the uptake of individual carotenoids within a mixed carotenoid formulation.

Подробнее
24-01-2013 дата публикации

Controlled Release Formulations of Opioids

Номер: US20130022646A1
Принадлежит: Individual

Pharmaceutical formulations containing opioid components that each has a release profile. The components may provide immediate or controlled release of the opioid. The invention is also directed to methods of controlling release of one or more opioid compounds and methods of treating pain.

Подробнее
28-02-2013 дата публикации

Formulations for oral delivery of adsorbents in the gut

Номер: US20130052269A1
Принадлежит: Da Volterra SAS

The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.

Подробнее
28-03-2013 дата публикации

ENCAPSULATION DEVICE, MEDICAL CAPSULES, AND ENCAPSULATION METHOD

Номер: US20130078308A1
Принадлежит: SEIKO EPSON CORPORATION

An encapsulation device includes: a fluid injection device that injects a first liquid forming a core; a liquid film holder that holds in film form a second liquid forming a shell containing the core; and a liquid contact device that makes the shell in contact with a third liquid, in which the first liquid is injected toward a liquid film of the second liquid retained by the liquid film holder to form a core, the core is wrapped with the second liquid on passing through the liquid film of the second liquid, thereby forming the shell, and the shell is made in contact with the third liquid to induce chemical reaction. 1. An encapsulation device comprising:a fluid injection device that injects a first liquid forming a core;a liquid film holder that holds in film form a second liquid forming a shell containing the core; anda liquid contact device that makes the shell in contact with a third liquid,the first liquid being injected toward a liquid film of the second liquid retained by the liquid film holder to form a core,the core being wrapped with the second liquid on passing through the liquid film of the second liquid, thereby forming the shell, andthe shell being made in contact with the third liquid to induce chemical reaction.2. The encapsulation device according to claim 1 , whereinthe liquid contact device has a liquid reservoir that reserves the third liquid in liquid form, andthe second liquid is made in contact with the third liquid by making the core wrapped with the second liquid to enter the liquid reservoir.3. The encapsulation device according to claim 1 , whereinthe liquid contact device has a mist generator that mists the third liquid in mist form, andthe second liquid is made in contact with the third liquid by misting the third liquid from the mist generator to an area, toward which the core wrapped with the second liquid is moved.4. The encapsulation device according to claim 2 , whereinthe second liquid is an aqueous solution containing a ...

Подробнее
04-04-2013 дата публикации

Taste masked pharmaceutical composition

Номер: US20130084332A1
Принадлежит: BOEHRINGER INGELHEIM VETMEDICA GMBH

This application relates to taste masked multi-layered particles an inert core, one or more coating layer(s) comprising a pharmaceutically active ingredient and a binder, an intermediate coating layer (seal coating) free from a low molecular weight water-soluble ionic compound and comprising a water-soluble pharmaceutical film-forming compound selected from (i) HPMC and PEG or (ii) PVP, and an outer coating layer (final or taste masking coating) free from a low molecular weight water-soluble ionic compound and comprising (i) a poly(meth)acrylate or (ii) a mixture comprising 60-90% (w/w) EC and 10-40% (w/w) HPMC, wherein the pharmaceutically active ingredient is water-soluble and comprises either at least one basic group and/or a bitter taste. Further disclosed are methods for the production of such particles and pharmaceutical compositions comprising them.

Подробнее
02-05-2013 дата публикации

Dual Controlled Release Dosage Form

Номер: US20130108693A1

A dosage form that provides a controlled release of at least two different active agents is provided. Particular embodiments include a dosage form that provides therapeutically effective levels of a first active agent and a second active agent in a mammal for an extended period of time following oral administration. An osmotic device containing a bi-layered core is provided. The osmotic device provides a dual controlled release of both drugs from the core. The layers of the core are in stacked, substantially concentric or substantially eccentric arrangement.

Подробнее
09-05-2013 дата публикации

Extended release compositions comprising as active compound venlafaxine hydrochloride

Номер: US20130115298A2
Автор: Yoram Sela
Принадлежит: Lycored Bio Ltd

The present invention relates to an extended release composition comprising as active compound Venlafaxine Hydrochloride, in which Venlafaxine Hydrochloride is coated on a non pareil inert core, which coated core is then coated with polymeric layer which enables the controlled release of the Venlafaxine Hydrochloride.

Подробнее
30-05-2013 дата публикации

Microcapsules and production thereof

Номер: US20130137626A1
Автор: Daniel Mues, Klaus Last

The invention relates to microcapsules, the capsule walls of which comprise a resin that can be obtained by reacting a) at least one compound selected from the group consisting of a1) amines and a2) aromatic or heteroaromatic compounds which are unsubstituted or substituted with one or more substituents from the group consisting of C 1 -C 20 -alkyl, OH, OR, COOH, SH, SR, NHCOR, OCOR, halogen, or an aromatic compound, where R is a C 1 -C 10 -alkyl group, with b) at least one aldehydic component that contains at least two carbons atoms per molecule, in the presence of c) at least one copolymer which contains units of 2-acrylamido-2-methylpropane sulphonic acid or salts (AMPS) thereof and/or 2-acrylamido-2-methylpropane phosphonic acid or salts (AMPP) thereof and units of one or more (meth)acrylates.

Подробнее
06-06-2013 дата публикации

BECLOMETHASONE DIPROPIONATE COMPOSITIONS IN MODIFIED-RELEASE GASTRO-RESISTANT MICROSPHERES AND PROCESS FOR OBTAINING THEM

Номер: US20130142880A1
Автор: LABRUZZO Carla
Принадлежит: SOFAR SPA

The present invention refers to pharmaceutical beclomethasone dipropionate compositions in modified-release gastro-resistant microspheres and to their oral use in the treatment of inflammatory pathologies of the intestinal tract. Said compositions in microspheres comprise: a) a core consisting of a microsphere of inert material; b) a first intermediate coating comprising beclomethasone dipropionate and at least one physiologically acceptable excipient; c) a second modified-release gastro-resistant coating. The present invention also refers to a process for obtaining said compositions. 1. A pharmaceutical composition in modified-release gastro-resistant microspheres , each microsphere comprising:a) a core consisting of a microsphere of inert material;b) a first intermediate coating comprising beclomethasone dipropionate and at least one physiologically acceptable excipient;c) a second modified-release gastro-resistant coating.2. A pharmaceutical composition according to claim 1 , wherein said microsphere of inert material has an average particle size of between 100 and 1000 microns claim 1 , preferably between 350 and 500 microns.3. A pharmaceutical composition according to claim 2 , wherein said inert material is a diluent.4. A pharmaceutical composition according to claim 3 , wherein said diluent is selected from microcrystalline cellulose claim 3 , saccharose claim 3 , corn starch claim 3 , lactose and/or a mixture thereof.5. A pharmaceutical composition according to claim 1 , wherein said at least one physiologically acceptable excipient is selected from suspending agents and/or glidants claim 1 , filming agents claim 1 , plasticizing agents and/or a mixture thereof6. A pharmaceutical composition according to claim 5 , wherein said suspending agents and/or glidants are selected from colloidal anhydrous silica claim 5 , talc and/or a mixture thereof.7. A pharmaceutical composition according to claim 5 , wherein said filming agents are selected from alkyl cellulose ...

Подробнее
20-06-2013 дата публикации

Formulations Preserving Bioactivity and Methods of Their Preparation

Номер: US20130156858A1
Принадлежит: RPH Pharmaceuticals AB

A pharmaceutical composition comprising an alginate hydrogel core where a bioactive agent is entrapped. The water content of the hydrogel is at least 10% of equilibrium water content. The beads have an enteric coating and are intended for oral administration. The bioactive agent is bioactive proteins, antibodies or viable cells and it is intended to exert its activity in the duodenum and the upper intestines.

Подробнее
27-06-2013 дата публикации

Composition and Method for Treating Neurological Disease

Номер: US20130165517A1
Принадлежит: Adamas Pharmaceuticals Inc

A method of treating a patient with Parkinson's disease is provided. The method comprises orally administering to the patient a first agent comprising levodopa and once-daily, orally administering to the patient a second agent comprising amantadine, or a pharmaceutically acceptable salt thereof. The amount of levodopa administered is reduced by 20% to 80% of the amount required in the absence of amantadine.

Подробнее
11-07-2013 дата публикации

Pharmaceutical compositions comprising hydromorphone and naloxone

Номер: US20130178492A1
Принадлежит: Euro Celtique SA

The present invention relates to prolonged release pharmaceutical dosage forms, the manufacture thereof as well as their use for administration to human beings.

Подробнее
25-07-2013 дата публикации

DRUG DELIVERY SYSTEMS AND METHODS OF USE

Номер: US20130189366A1
Принадлежит:

Disclosed herein are systems for delivery of one or more molecules (such as a drug, for example, a small molecule, polypeptide, and/or nucleic acid) to a subject, for example to a targeted location in the subject. In some embodiments, the delivery system includes an encapsulated inducing agent or repressing agent and a plurality of cells. In some examples, the inducing agent or repressing agent and the cells are each separately encapsulated. In other examples, the encapsulated inducing agent or repressing agent and the cells are co-encapsulated. The cells include one or more genes which are operably linked to an inducible promoter or a repressible promoter which is inducible or repressible by the encapsulated inducing agent or repressing agent, respectively. Methods of use of the delivery systems, for example to treat or inhibit a disease or disorder in a subject, are also disclosed. 1. A drug delivery system comprising:an encapsulated inducing agent or repressing agent; andan encapsulated plurality of cells, wherein the cells comprise a gene operably linked to a promoter inducible by the inducing agent or repressible by the repressing agent, and wherein the expression of the gene is modified by the inducing agent or the repressing agent.2. The drug delivery system of claim 1 , wherein the encapsulated inducing agent and the encapsulated plurality of cells are co-encapsulated.3. The drug delivery system of claim 1 , wherein the encapsulated inducing agent or repressing agent is encapsulated in one or more microspheres comprising a polymer.4. The drug delivery system of claim 3 , wherein the polymer comprises poly(lactic-co-glycolic acid) (PLGA).5. The drug delivery system of claim 1 , wherein the encapsulated plurality of cells is encapsulated in a microcapsule comprising a polymer.6. The drug delivery system of claim 5 , wherein the polymer comprises alginate claim 5 , collagen claim 5 , chitosan claim 5 , gelatin claim 5 , agarose claim 5 , or a combination of two ...

Подробнее
01-08-2013 дата публикации

WATER-SOLUBLE MELOXICAM GRANULES

Номер: US20130193028A1
Принадлежит: BOEHRINGER INGELHEIM VETMEDICA GMBH

Water soluble meloxicam granules include meloxicam, a salt forming agent which forms the meglumine, sodium, potassium, or ammonium salt of meloxicam, a binder, a sugar or sweetener, and a carrier, and a flavoring agent. 1. A method of treating animals comprising administering water soluble granules to an animal , the water soluble granules comprising meloxicam; a salt forming agent operable to form a meloxicam salt; a binder; and a carrier.2. The method according to further comprising dissolving the water soluble granules in water prior to administration.3. The method according to further comprising mixing the water soluble granules with animal feed prior to administration.4. The method according to claim 1 , wherein the salt forming agent is selected from the group consisting of meglumine claim 1 , sodium claim 1 , potassium claim 1 , or ammonium meloxicam salt.5. The method according to claim 1 , wherein the salt forming agent is meglumine.6. The method according to claim 1 , wherein the binder is selected from hydroxypropylmethylcellulose claim 1 , polyvinylpyrrolidone claim 1 , gelatine claim 1 , starch claim 1 , or polyethylene glycol ether.7. The method according to claim 6 , wherein the binder is present in an amount of 20 mg/g to 150 mg/g.8. The method according to claim 1 , wherein the water soluble granules are administered in conjunction with antibiotic treatment.9. The method according to claim 1 , wherein the animal includes horses claim 1 , pigs claim 1 , cattle claim 1 , dogs claim 1 , or cats.10. The method according to claim 1 , wherein the meloxicam granules comprises meloxicam claim 1 , meglumine claim 1 , hydroxypropylmethylcellulose claim 1 , povidone claim 1 , and glucose monohydrate.11. The method according to claim 1 , wherein the granules possess a particle size distribution of 125 μm to 500 μm.12. The method according to claim 1 , wherein:the salt forming agent is meglumine;the molar ratio of meglumine and meloxicam is 9:8 to 12:8.13. An ...

Подробнее
08-08-2013 дата публикации

Pharmaceutical composition for the prolonged release of trimetazidine

Номер: US20130202710A1
Принадлежит: Laboratoires Servier SAS

Composition for the prolonged release of trimetazidine wherein the inner phase comprises trimetazidine and the outer layer comprises a retardant and an anti-agglomerant.

Подробнее
22-08-2013 дата публикации

PHARMACEUTICAL COMPOSITIONS OF (R)-LANSOPRAZOLE

Номер: US20130216617A1
Принадлежит: CADILA HEALTHCARE LIMITED

The present invention relates to stable pharmaceutical compositions of (R)-lansoprazole or pharmaceutically acceptable salts thereof and process of preparing the same. The invention particularly provides pharmaceutical compositions of optically active (R)-isomer of lansoprazole with at least two functional coating layers. 1. A stable pharmaceutical composition comprising a core comprising (R)-lansoprazole or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients; and at least two functional coating layers over the core , wherein the first functional coating layer comprises a polymeric substance which is soluble in the pH range of 6.0 to 7.5 and the second functional coating layer comprises a polymeric substance which is soluble in the pH range of 5.0 to 6.0.2. The stable pharmaceutical composition as claimed in claim 1 , wherein the core comprises an inert core coated with (R)-lansoprazole or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients.3. The stable pharmaceutical composition as claimed in claim 1 , wherein the composition further comprises at least one drug layer comprising (R)-lansoprazole or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients.4. The stable pharmaceutical composition as claimed in claim 3 , wherein the drug layer is formed over the first functional coating layer.5. The stable pharmaceutical composition as claimed in claim 1 , wherein the polymeric substance comprises one or more of hydroxypropylmethyl cellulose phthalate claim 1 , cellulose acetate phthalate claim 1 , carboxymethylethyl cellulose claim 1 , methyl methacrylate-methacrylic acid copolymer claim 1 , methacrylic acid-ethyl acrylate copolymer claim 1 , methacrylic acid-methyl acrylate-methyl methacrylate copolymer claim 1 , hydroxypropyl cellulose acetate succinate claim 1 , polyvinyl acetate phthalate and shellac.6. The stable pharmaceutical ...

Подробнее
05-09-2013 дата публикации

Tdf-related compounds and analogs thereof, analogs and bioactive fragments

Номер: US20130231294A1
Принадлежит: Individual

The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules, which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders.

Подробнее
19-09-2013 дата публикации

Stable Corticosteroid Nanoparticulate Formulations and Methods for the Making and Use thereof

Номер: US20130243830A1
Принадлежит: Marinus Pharmaceuticals Inc

Disclosed are stable corticosteroid nanoparticulate formulations, methods of making and therapeutic uses thereof.

Подробнее
19-09-2013 дата публикации

HYDROXYALKYL CELLULOSE

Номер: US20130243870A1
Автор: Abe Satoru, Kato Takashi
Принадлежит: NIPPON SODA CO., LTD.

The present invention provides a hydroxyalkyl cellulose having a viscosity of 1.10 mPa·s to 1.95 mPa·s in a 2%-concentration aqueous solution at 20° C., and a solid formulation containing the hydroxyalkyl cellulose. 1. A hydroxyalkyl cellulose that has a viscosity of 1.10 mPa·s to 1.95 mPa·s in a 2%-concentration aqueous solution at 20° C.2. A solid formulation comprising the hydroxyalkyl cellulose according to .3. The solid formulation according to claim 2 , whereinthe solid formulation is a tablet.4. The solid formulation according to claim 2 , whereinthe content of the hydroxyalkyl cellulose in the solid formulation is 1% by weight to 30% by weight.5. Coating particles comprising:core particles; anda coating layer that covers the core particles, whereinthe coating layer contains a hydroxyalkyl cellulose that has a viscosity of 1.10 mPa·s to 1.95 mPa·s in a 2%-concentration aqueous solution at 20° C.6. The coating particles according to claim 5 , whereina volume average primary particle size of the core particles 5 μm to 1000 μm.7. The coating particles according to claim 5 , whereinthe content of the hydroxyalkyl cellulose in the coating layer is 1% by weight to 50% by weight.8. The coating particles according to claim 5 , whereinthe coating layer further contains drug particles.9. The coating particles according to claim 8 , whereina volume average primary particle size of the drug particles is smaller than a volume average primary particle size of the core particles. The present invention relates to a hydroxyalkyl cellulose that is suitable for producing an orally-disintegrating agent, a gastro-soluble solid formulation, an entero-soluble solid formulation, a slow-release solid formulation, a bitterness-suppressing solid formulation, and the like.Priority is claimed on Japanese Patent Application No. 2010-270172, filed Dec. 3, 2010, the content of which is incorporated herein by reference.A method of producing an orally-disintegrating agent or the like, which ...

Подробнее
19-09-2013 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20130245055A1

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Подробнее
26-09-2013 дата публикации

COMPOSITION COMPRISING A BENZIMIDAZOLE AND PROCESS FOR ITS MANUFACTURE

Номер: US20130251791A1
Автор: Schmitt Benoit, Seth Pawan
Принадлежит:

The invention provides new benzimidazole compositions, comprising: (a) a core containing said benzimidazole active ingredient; (b) an intermediate layer; and (c) an enteric layer; said core being substantially free of binder. The invention also provides a process for manufacturing the composition of the invention. 1. A pharmaceutical composition comprising:(a) a core that is free of binder and free of PVP as a binder and/or HPMC;(b) an intermediate layer; and(c) an enteric layer; about 10 to about 80 parts of a benzimidazole active ingredient in an alkaline salt form,', 'about 20 to about 85 parts of a first, water-soluble, diluent,', '0 to about 80 parts of a second, water-insoluble, diluent,', 'about 10 to about 40 parts of a disintegrant, and', '0 to about 5 parts of a lubricant., 'wherein the core consists essentially of, by weight2. The composition of claim 1 , wherein the second claim 1 , water-insoluble claim 1 , diluent is present in an amount up to about 80 parts claim 1 , by weight.3. The composition of claim 2 , wherein the core consists essentially of claim 2 , by weight:about 15 to about 60 parts of said benzimidazole active ingredient,about 40 to about 75 parts of the first, water-soluble, diluent,up to about 40 parts of the second, water-insoluble, diluent,about 15 to about 30 parts of the disintegrant, andabout 0.5 to about 5 parts of the lubricant.4. The composition of claim 2 , wherein the first diluent and the second diluent are present in a weight ratio of about 1.5:1 to 1:1.5.5. The composition of claim 2 , wherein the first claim 2 , water-soluble claim 2 , diluent comprises lactose and the second claim 2 , water-insoluble claim 2 , diluent comprises cellulose acetate.6. The composition of claim 2 , wherein the disintegrant comprises cross-linked polyvinylpyrrolidone.7. The composition of claim 1 , wherein the core consists essentially of claim 1 , by weight:about 15 to about 60 parts of said benzimidazole active ingredient,about 40 to about 75 ...

Подробнее
17-10-2013 дата публикации

Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral Administration

Номер: US20130273169A1
Принадлежит: Ironwood Pharmaceuticals Inc

Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.

Подробнее
17-10-2013 дата публикации

Oral formulation for dexlansoprazole

Номер: US20130273171A1
Принадлежит: Handa Pharmaceuticals LLC

A stable formulation of dexlansoprazole for treating a digestive disorder, and methods of manufacturing the same.

Подробнее
31-10-2013 дата публикации

Liquid ganaxolone formulations and methods for the making and use thereof

Номер: US20130287851A1
Принадлежит: Marinus Pharmaceuticals Inc

In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.

Подробнее
28-11-2013 дата публикации

LIPID-POLYMER HYBRID PARTICLES

Номер: US20130315831A1
Принадлежит:

A particle includes an aqueous core; a first amphiphilic layer surrounding the aqueous core; and a polymeric matrix surrounding the first amphiphilic layer. 1. A particle comprising:an aqueous core;a first amphiphilic layer surrounding the aqueous core; anda polymeric matrix surrounding the first amphiphilic layer.2. The particle of claim 1 , further comprising a second amphiphilic layer surrounding the polymeric matrix.3. The particle of claim 1 , wherein the particle has an average diameter between about 40 nm and about 400 μm.4. (canceled)5. The particle of claim 1 , wherein the first amphiphilic layer is a multilayer.6. The particle of claim 1 , wherein the first amphiphilic layer comprises naturally derived lipids claim 1 , surfactants claim 1 , or synthesized compounds with both hydrophilic and hydrophobic moieties.7. The particle of claim 1 , wherein the first amphiphilic layer comprises 1 claim 1 ,2-dimyristoleoyl-sn-glycero-3-ethylphosphocholine (EPC14:1).8. The particle of claim 1 , wherein the first amphiphilic layer has a thickness of about 1 nm to about 50 nm.9. The particle of claim 1 , wherein the polymeric matrix comprises poly(lactide-co-glycolide) (PLGA) claim 1 , a polyalkylene glycol claim 1 , or a polyester.10. The particle of claim 1 , wherein the polymeric matrix comprises polyethylenes claim 1 , polycarbonates claim 1 , polyanhydrides claim 1 , polyhydroxyacids claim 1 , polypropylfumerates claim 1 , polycaprolactones claim 1 , polyamides claim 1 , polyacetals claim 1 , polyethers claim 1 , polyesters claim 1 , poly(orthoesters) claim 1 , polycyanoacrylates claim 1 , polyvinyl alcohols claim 1 , polyurethanes claim 1 , polyphosphazenes claim 1 , polyacrylates claim 1 , polymethacrylates claim 1 , polycyanoacrylates claim 1 , polyureas claim 1 , polystyrenes claim 1 , or polyamines claim 1 , or combinations thereof.1113.-. (canceled)14. The particle of claim 9 , wherein the polyester is poly(lactide-co-glycolide) (PLGA) claim 9 , polylactic ...

Подробнее
05-12-2013 дата публикации

Sustained Release Composition of Memantine

Номер: US20130323309A1
Принадлежит: Lupin Limited

A sustained release pharmaceutical composition comprising; a core including memantine or its pharmaceutically acceptable salts and one or more pharmaceutical acceptable excipients, and a sustained release coating comprising a water insoluble substance and a water soluble substance where the ratio of the water insoluble substance to the water soluble substance is from about 1:0 to about 3:5:1, optionally containing an immediate release coating having memantine where the immediate release coating is applied over the sustained release coating. 1. A sustained release pharmaceutical composition comprising:a. a core comprising memantine or its pharmaceutically acceptable salts and one or more pharmaceutical acceptable excipients, andb. a sustained release coating comprising a water insoluble substance and a water soluble substance, wherein a ratio of the water insoluble substance to the water soluble substance is from about 1:0 to about 3.5:1.2. The sustained release pharmaceutical composition of wherein the water soluble substance is selected from hydroxylpropyl methyl cellulose claim 1 , hydroxypropyl cellulose claim 1 , polyvinylpyrrolidone claim 1 , polyvinyl alcohol claim 1 , sodium lauryl sulphate claim 1 , polyethylene glycol claim 1 , sugars claim 1 , lactose claim 1 , sucrose claim 1 , fructose claim 1 , mannitol claim 1 , carrageenans claim 1 , galactomannans claim 1 , tragacanth claim 1 , agar-agar claim 1 , gum arabic claim 1 , guar gum claim 1 , xanthan gum claim 1 , starches claim 1 , pectins or mixtures thereof.3. The sustained release pharmaceutical composition of wherein water insoluble substance is selected from ethyl cellulose claim 1 , cellulose acetates claim 1 , polymethacrylates containing quaternary ammonium group claim 1 , hydrogenated vegetable oil claim 1 , gelucire claim 1 , polyvinyl acetate claim 1 , cellulose acetate butyrate or mixtures thereof.4. The sustained release pharmaceutical composition of further comprising a seal coating between ...

Подробнее
02-01-2014 дата публикации

COATED DRUG SPHEROIDS AND USES THEREOF FOR ELIMINATING OR REDUCING CONDITIONS SUCH AS EMESIS AND DIARRHEA

Номер: US20140004203A1
Принадлежит: WYETH LLC

The present invention provides an oral pharmaceutical formulation comprising coated spheroids of a kinase inhibitor such as neratinib, which formulation is designed to reduce or eliminate side effects associated with existing oral formulations of kinase inhibitors. 1. A pharmaceutically acceptable composition of (i) spheroid particles comprising: (a) 30-70 weight percent of (E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide or a pharmaceutically acceptable salt thereof; (b) 20-30 weight percent of one or more fillers; and (c) 5-15 weight percent of one or more wetting agents , said spheroid particles comprising 70-83 weight percent of the total composition; (ii) a sub-coating applied to said spheroid particles further comprising 1-4 weight percent of one or more pharmaceutically acceptable cellulose based polymers and (iii) 16-30 weight percent of one or more pharmaceutically acceptable polymers as an enteric coating applied to said sub-coating , said coating components (ii) and (iii) comprising 17-30 weight percent of the total composition.2. A pharmaceutically acceptable composition of (i) spheroid particles comprising: (a) 30-70 weight percent of (E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate; (b) 20-30 weight percent of microcrystalline cellulose; and (c) 5-15 weight percent of a polysorbate , said spheroid particles comprising 70-84 weight percent of the total composition; (ii) a sub-coating applied to said spheroid particles further comprising 1-4 weight percent of hydroxypropylcellulose and (iii) 16-30 weight percent of a methacrylic acid polymer as an enteric coating applied to said sub-coating , said coating components (ii) and (iii) comprising 16-30 weight percent of the total composition.3. The composition according to claim 2 , wherein the weight percent of (E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3 ...

Подробнее
09-01-2014 дата публикации

Multi-encapsulated formulations made with oxidized cellulose

Номер: US20140010755A1
Принадлежит: Confluent Surgical Inc

A microsphere and method for forming the same are disclosed. The microsphere includes modified cellulose and at least one of a visualization agent, a magnetic material, or a radioactive material.

Подробнее
30-01-2014 дата публикации

Formulations and Methods for Attenuating Respiratory Depression Induced by Opioid Overdose

Номер: US20140030343A1
Принадлежит: ALPHARMA PHARMACEUTICALS LLC

The invention relates to compositions and methods for attenuating opioid induced respiratory depression. Such compositions comprise opioids and sequestered opioid antagonists in a multi-particulate dosage formulation. 2. The formulation of wherein the attenuation of respiratory depression is measured by reduction in PCO.3. The formulation of wherein the reduction in PCOis at least 5%.4. The formulation of wherein attenuation of respiratory depression is measured by an increase in oxygen saturation (SpO) levels.5. The formulation of wherein the opioid is morphine or a pharmaceutically acceptable salt of morphine.6. The formulation of wherein the opioid is oxycodone or a pharmaceutically acceptable salt of oxycodone.8. The formulation of wherein the attenuation of respiratory depression is measured by reduction in PCO.9. The formulation of wherein the reduction in PCOis at least 5%.10. The formulation of wherein attenuation of respiratory depression is measured by an increase in oxygen saturation (SpO) levels.11. The formulation of wherein the opioid is morphine or a pharmaceutically acceptable salt of morphine.12. The formulation of wherein the opioid is oxycodone or a pharmaceutically acceptable salt of oxycodone. King Pharmaceuticals' deactacore platform, the incorporation of sequestered naltrexone into the core of a controlled-release opioid dosage form which is released only upon disruption of the sequestering polymer matrix, was developed as a means of reducing the effect of excess opioid and drug liking when the product is misused or abused. The deactacore technology is described in detail in U.S. Pat. Nos. 7,682,633 and 7,682,634 US Patent Publication Nos. US 20080233156, US 20090131466, US 20040131552, US 20100152221, US 20100151014 and US 20100143483 and PCT Application Nos. PCT/US08/087030 PCT/US08/087043, PCT/US08/87047, and PCT/US08/087055 incorporated herein by reference.The analgesic drug Embeda® (also referred to as ALO-01) is an example a marketed ...

Подробнее
06-02-2014 дата публикации

CONTROLLED RELEASE COMPOSITIONS OF GAMMA-HYDROXYBUTYRATE

Номер: US20140037745A1
Принадлежит: Supernus Pharmaceuticals, Inc.

The present invention is directed to oral pulse-release pharmaceutical dosage form containing an immediate release component of gamma-hydroxybutyric acid, and one or more delayed/controlled release components of gamma-hydroxybutyric acid. 156.-. (canceled)57. An oral pharmaceutical dosage form , comprising (a) an immediate release component comprising gamma-hydroxybutyric acid (GHB) , and (b) a delayed release component comprising GHB.58. The oral dosage form of claim 57 , wherein said delayed release component comprises particles containing GHB in a core claim 57 , which core is immediately surrounded by a barrier coat to control the migration of GHB from the core claim 57 , which in turn is surrounded by an enteric release coat that releases GHB at a predetermined pH after ingestion.59. The oral dosage form of claim 58 , wherein said barrier coat contains a neutralizing agent or agents selected from the group consisting of malic acid claim 58 , citric acid claim 58 , tartaric acid claim 58 , ascorbic acid claim 58 , oleic acid claim 58 , capric acid claim 58 , caprylic acid claim 58 , benzoic acid claim 58 , a polyacid claim 58 , and acidic ionic resins.60. The oral dosage form of claim 59 , wherein the neutralizing agent(s) are used in amounts sufficient to neutralize any migrating gamma-hydroxybutyric acid salts.61. The oral dosage form of claim 60 , wherein said neutralizing agent(s) are used in an amount of about 0.01% to about 10% mol/mol of the GHB.62. The oral dosage form of claim 61 , wherein the amount is from about 1% to about 5% mol/mol of the GHB.63. The oral dosage form of claim 58 , wherein the barrier coat is composed of materials selected from ethylcellulose claim 58 , methylcellulose claim 58 , hydroxypropyl cellulose claim 58 , hydroxypropyl methylcellulose claim 58 , cellulose acetate claim 58 , cellulose acetate phthalate claim 58 , polyvinyl alcohol claim 58 , or other water-based or solvent-based coating materials.64. The oral dosage form of ...

Подробнее
27-02-2014 дата публикации

DRUG DELIVERY SYSTEM

Номер: US20140056962A1
Принадлежит: Merck Sharp & Dohme B.V.

The subject invention provides a drug delivery system comprising at least one compartment comprising (i) a drug-loaded thermoplastic polymer core layer, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said core layer is loaded with crystals of a first (pharmaceutically) active compound and said intermediate layer is loaded with crystals of the second (pharmaceutically) active compound. 159-. (canceled)60. A drug delivery system comprising (i) a drug-loaded ethylene-vinyl acetate copolymer core layer , (ii) a drug-loaded ethylene-vinyl acetate copolymer intermediate layer and (iii) a non-medicated ethylene-vinyl acetate copolymer skin covering the intermediate layer , wherein the core layer is loaded with crystals of estradiol , and wherein the intermediate layer is loaded with crystals of nomegestrol acetate (NOMAc).61. The drug delivery system of claim 60 , wherein the core layer forms the core of the drug delivery system.62. The drug delivery system of claim 60 , wherein an additional non-medicated core is covered by the core layer.63. The drug delivery system of claim 60 , wherein an additional non-medicated intermediate layer is between the core layer and the drug-loaded intermediate layer.64. The drug delivery system of claim 60 , wherein the delivery system has the form of a ring claim 60 , an implant claim 60 , an intrauterine system (IUS) claim 60 , a helical coil or a spring.65. The drug delivery system of claim 64 , wherein the delivery system has a substantially ring-shaped form and is intended for vaginal administration.66. The drug delivery system of claim 60 , wherein nomegestrol acetate is present at about 5-35% by weight.67. The drug delivery system of claim 60 , wherein nomegestrol acetate is present at about 35% by weight.68. The drug delivery system of claim 60 , wherein the estradiol is present at about 3-27% by weight.69. The drug delivery ...

Подробнее
13-03-2014 дата публикации

Unit dose form for oral administration

Номер: US20140072624A1
Принадлежит: Threshold Pharmaceuticals Inc

Formulations and unit dose forms of TH-302 and other hypoxia activated prodrugs suitable for oral administration are useful for treating cancer.

Подробнее
27-03-2014 дата публикации

WATER-SOLUBLE DRUG CARRIER AND PROCESS FOR PRODUCING THE SAME

Номер: US20140086996A1

An object of the present invention is to provide a drug delivery carrier that is free from the drug leakage problem and has an easily controllable particle size, and that can be used to deliver water-soluble drugs such as genes and proteins in a wide range of applications, including delivery of water-soluble drugs that do not have high anionic properties, and also can be used as a non-viral gene vector. The invention also provides a process for production of such drug delivery carriers. The drug delivery carrier of the present invention includes a water-soluble drug double-coated with two types of inner and outer surfactants 1 and 2. 1. A drug delivery carrier that comprises a water-soluble drug double-coated with two types of inner and outer surfactants 1 and 2.2. The drug delivery carrier according to claim 1 , wherein the water-soluble drug is any one of protein claim 1 , gene claim 1 , oligonucleic acid claim 1 , polysaccharide claim 1 , synthetic polymer claim 1 , peptide claim 1 , small molecule claim 1 , and nanoparticle (ultrastructure).3. The drug delivery carrier according to claim 2 , wherein the gene is a pDNA claim 2 , and wherein the protein is an EGFP.4. The drug delivery carrier according to claim 1 , wherein the inner surfactant 1 is any one of sucrose fatty acid ester claim 1 , cholesterol claim 1 , and glycerin fatty acid ester.5. The drug delivery carrier according to claim 1 , wherein the outer surfactant 2 is at least one of PC claim 1 , L-1695 claim 1 , PEG(2K)-MS claim 1 , PEG(2K)-DSPE claim 1 , PEG(5K)-DSPE claim 1 , PEG(comb)-DSPE claim 1 , Tween 80 claim 1 , sodium dodecyl sulfate claim 1 , and glycerin fatty acid ester.6. The drug delivery carrier according to claim 1 , wherein the drug delivery carrier includes at least one of hydrophobic molecules such as DOPE and dinitrochlorobenzene claim 1 , and cationic polymers such as PEI and poly-L-lysine.7. The drug delivery carrier according to claim 1 , wherein the drug delivery carrier is ...

Подробнее
03-04-2014 дата публикации

COMPOSITIONS AND METHODS OF MAKING SUSTAINED RELEASE LIQUID FORMUALTIONS

Номер: US20140093577A1
Принадлежит: NEOS THERAPEUTICS, LP

The present invention includes compositions and methods for the controlled release of active agents in a shelf-stable liquid formulation by blending one or more controlled release microbeads comprising one or more active agents, preparing a dense, thixotropic solution having a density that is at, or about, the density of the one or more microbeads comprising a thixotropic agent, water and one or more preservatives under conditions that reduce bubble formation and mixing the microbeads and the thixotropic solutions in a mixer that lacks scraping paddles. 134-. (canceled)35. A liquid , controlled-release formulation comprising controlled release microbeads comprising one or more active agents in coated drug-resin complexes and a dense , thixotropic solution having a density that is at or about the density of the one or more microbeads , said dense , thixotropic solution comprising a thixotropic agent , water and one or more preservatives ,wherein said formulation is shelf-stable and has a uniform appearance with no visible lumps, andfurther wherein said formulation is made by the method ofobtaining one or more controlled release microbeads comprising one or more active agents in coated drug-resin complexes;preparing a dense, thixotropic solution having a density that is at or about the density of the one or more microbeads, wherein the dense, thixotropic solution comprises a thixotropic agent, water and one or more preservatives, under conditions that reduce bubble formation; andmixing the microbeads and the thixotropic solutions under conditions that minimize the introduction of bubbles in the liquid.36. The liquid formulation of claim 35 , wherein the one or more active agents comprises pseudoephedrine claim 35 , an antihistamine claim 35 , chlorpheniramine claim 35 , dextromethorphan claim 35 , an analgesic claim 35 , an antitussive claim 35 , or salts thereof or mixtures thereof.3743-. (canceled)44. A liquid claim 35 , controlled-release formulation comprising ...

Подробнее
06-01-2022 дата публикации

BIOMASS-BASED ENCAPSULATING MATERIAL FOR PROTECTION OF PROBIOTIC ACTIVITY AND AN ENCAPSULATING METHOD

Номер: US20220000793A1

A biomass-based encapsulating material for protection of probiotic activity and an encapsulating method are disclosed. The biomass-based encapsulating material includes a nano-film having two layers for encapsulating probiotics. A first layer is formed through natural biological macromolecules and metal ions on surfaces of the probiotics by covalent cross-linking or metal chelating action in situ, and a second layer is formed by interactions between a bio-enzyme and the natural biological macromolecules. The nano-film formed in situ on cell walls of probiotics is used for encapsulation and protection of probiotics. The nano-film is made of natural biomass, has low cost and has no toxic side effects. The relative activity of encapsulated probiotics is close to or higher than 90%, whether they are cultivated in environments under high concentration of antibiotics or active-free radicals. The relative activity of unprotected probiotics is below 30%, or even completely unable to survive. 1. A biomass-based encapsulating material for protection of probiotic activity , comprising a nano-film for encapsulating probiotics , the nano-film comprising two layers , wherein a first layer is formed through natural biological macromolecules and metal ions on surfaces of the probiotics by covalent cross-linking or metal chelating action in situ , and a second layer is formed by interactions between a bio-enzyme and the natural biological macromolecules.2. The biomass-based encapsulating material for protection of probiotic activity according to claim 1 , wherein the bio-enzyme is one of or a mixture of two or more of β-galactosidase claim 1 , amylopsin claim 1 , α-glucosaccharase claim 1 , β-glucosaccharase claim 1 , pancreatic lipase claim 1 , trypsin and cellulase at any proportion.3. The biomass-based encapsulating material for protection of probiotic activity according to claim 1 , wherein the metal ions are one of or a mixture of two or more of cations of Al claim 1 , Fe claim ...

Подробнее
03-01-2019 дата публикации

Methods and Compositions Particularly for Treatment of Attention Deficit Disorder

Номер: US20190000769A1
Принадлежит:

There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described. 1. A method of treating attention deficit hyperactivity disorder (ADHD) in a subject in need thereof , the method comprising orally administering to the subject a dosage form providing 25 , 30 , 35 , 45 , 55 , 75 , 85 , or 100 mg methylphenidate hydrochloride and means for providing an in vivo methylphenidate Tof about 3 hours and Tof about 13.5 hours in the fed state.2. The method of claim 1 , wherein the in vivo methylphenidate Tof about 3 hours and Tof about 13.5 hours are achieved after a single oral administration of the dosage form.3. The method of claim 1 , wherein the dosage form releases a first portion of the methylphenidate hydrochloride immediately upon oral administration.4. The method of claim 3 , wherein the dosage form releases a second portion of the methylphenidate hydrochloride in a controlled and delayed release manner after oral administration.5. The method of claim 4 , wherein about 20% by weight of the methylphenidate hydrochloride in the dosage form is released as the first portion.6. The method of claim 5 , wherein about 80% by weight of the ...

Подробнее
03-01-2019 дата публикации

PULSATILE RELEASE PHARMACEUTICAL COMPOSITION COMPRISING NAFTAZONE OR ONE OF ITS SALTS

Номер: US20190000784A1
Принадлежит:

Disclosed is a pharmaceutical composition including naftazone or one of its pharmaceutically acceptable salts, for its use for the pulsatile release of naftazone or one of its pharmaceutically acceptable salts, wherein: a first pulse of naftazone or one of its pharmaceutically acceptable salts is released substantially immediately upon oral administration of the pharmaceutical composition; and at least one additional pulse of naftazone or one of its pharmaceutically acceptable salts is released at about 3 hours to about 8 hours following the oral administration. 117-. (canceled)18. A method for the pulsatile release of naftazone or one of its pharmaceutically acceptable salts , pharmaceutical composition comprising naftazone or one of its pharmaceutically acceptable salts , wherein:a first pulse of naftazone or one of its pharmaceutically acceptable salts is released substantially immediately upon oral administration of said pharmaceutical composition, andat least one additional pulse of naftazone or one of its pharmaceutically acceptable salts is released at about 3 hours to about 8 hours following said oral administration.19. A bi-pulsatile release pharmaceutical composition comprising:at least one immediate-release pharmaceutical system containing naftazone or one of its pharmaceutically acceptable salts, that provides a first pulse of naftazone or one of its pharmaceutically acceptable salts, andat least one controlled-release pharmaceutical system containing naftazone or one of its pharmaceutically acceptable salts, that provides a second pulse of naftazone or one of its pharmaceutically acceptable salts, wherein:the first pulse is released substantially immediately upon oral administration,the second pulse is released at about 3 hours to about 8 hours following oral administration.20. The pharmaceutical composition of claim 19 , wherein the immediate-release pharmaceutical system contains at least 40 mg of naftazone claim 19 , and wherein the controlled- ...

Подробнее
04-01-2018 дата публикации

Pulsed Release Phenylephrine Dosage Forms

Номер: US20180000752A1
Принадлежит:

A multi-particle dosage form that can deliver phenylephrine in controlled pulsed doses. The dosage form can contain an immediate release form that can contain phenylephrine or a salt thereof and a plurality of delayed release particles with a coating that can contain phenylephrine or salt thereof and a pH sensitive coating. 1. An oral dosage form comprising:a. an immediate release form comprising about 10 mg to about 20 mg phenylephrine or a pharmaceutically acceptable salt thereof; and i. a core;', 'ii. a phenylephrine coating comprising phenylephrine or a pharmaceutically acceptable salt thereof;', 'iii. a pH sensitive coating comprising an acrylate copolymer selected from the group consisting of methyl-methacrylate esters copolymerized with methacrylic acid, acrylic acid and esters copolymerized with methacrylic acid and esters, ammonio-containing acrylate copolymers, and combinations thereof;', 'wherein each delayed release particle comprises from about 30 wt. % to about 60 wt. % of the pH sensitive coating, by weight of the delayed release particle;', 'wherein the plurality of delayed release particles comprise from about 7 mg to about 15 mg phenylephrine or a pharmaceutically acceptable salt thereof., 'b. a plurality of delayed release particles wherein each delayed release particle comprises2. The oral dosage form of wherein each delayed release particle comprises from about 30 wt. % to about 55 wt. % of the pH sensitive coating claim 1 , by weight of the delayed release particle.3. The oral dosage form of wherein each delayed release particle comprises from about 40 wt. % to about 50 wt. % of pH sensitive coating claim 2 , by weight of the delayed release particle.4. The oral dosage form of wherein each delayed release particle further comprises a separation coating between the phenylephrine coating.5. The oral dosage form of wherein the separation coating is selected from the group consisting of talc claim 4 , polyvinyl alcohol-polyethylene glycol graft co- ...

Подробнее
02-01-2020 дата публикации

GASTRORESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN

Номер: US20200000726A1
Принадлежит:

The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5:0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease. 117.-. (canceled)18. A method for preparing gastroresistant microgranule of rifaximin , the method comprising spraying on rifaximin microgranules an aqueous suspension containing a gastroresistant polymer insoluble over a pH range of from 1.5 to 4.0 and soluble over a pH range from 5.0 to 7.5 together with pharmaceutically acceptable excipients , the spraying performed in a fluid apparatus , in which air flows , to obtain the gastroresistant microgranule of rifaximin directly coated with the gastroresistant polymer in which the rifaximin is retained at pH lower than 4.0 and is released at pH higher than 5.19. The method of claim 18 , wherein the air flow is in entrance at a temperature between 50° C. and 75° C. and with an output 450 and 650 mper hour under a pressure between 1.0 and 1.5 bar and a flow speed between 150 and 300 g/min through a nozzle on the mixture of rifaximin maintained in a suspension fluid bed apparatus.20. The method of wherein the product temperature during the spraying is maintained at a value between 20° C. and 40° C.21. The method according of wherein the air temperature in entrance is at a temperature between 60° C. and 70° C.22. The method of claim 18 , wherein the gastroresistant polymer is selected in the group consisting of cellulose acetate phthalate claim 18 , hydroxypropyl cellulose acetate phthalate claim 18 , hydroxypropyl methylcellulose phthalate claim 18 , polyvinyl acetate phthalate claim 18 , co-polymers of methacrylic acid and combinations thereof.23. The method of wherein the gastroresistant microgranules have a ...

Подробнее
02-01-2020 дата публикации

Composition for controlled release of physiologically active substances and process for its preparation

Номер: US20200000733A1
Принадлежит: Bioscreen Technologies SRL

The present invention relates to a rumen-resistant composition in the form of microgranules, a process for its production and a feedstuff containing such composition.

Подробнее
13-01-2022 дата публикации

COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS

Номер: US20220008441A1
Автор: Habboushe Joseph
Принадлежит:

Provided are compositions and methods for treating multiple sclerosis (MS). One embodiment of the disclosed method entails orally administering to a MS patient a first amount of aspirin and a second amount of fumaric acid or an ester or a salt thereof. In some embodiments, the aspirin is administered at from about 80 mg to about 500 mg per day and the fumaric acid or ester or salt thereof is administered at about 360 mg per day. 111-. (canceled)12. A capsule comprising a dosage form comprising an effective amount of aspirin and an effective amount a fumaric acid or an ester or a salt thereof , wherein the aspirin and fumaric acid or an ester or a salt thereof are each individually formulated as enterically coated microspheres contained within a capsule shell.13. The capsule of claim 12 , wherein the capsule is coated with a second dose of aspirin formulated to dissolve in an oral cavity of a subject.14. The capsule of claim 13 , comprising from about 20 mg to about 500 mg of aspirin.15. A method of treating multiple sclerosis (MS) in a human patient in need thereof claim 13 , comprising orally administering to the patient a dosage form comprising aspirin and fumaric acid or an ester or a salt thereof claim 13 , wherein the aspirin is administered at from about 150 mg to about 650 mg per day and the fumaric acid or ester or salt thereof is administered at about 300 mg to about 450 mg per day.16. The method of claim 15 , wherein at least a portion of the aspirin is formulated to dissolve in an oral cavity of a subject.17. The method of or claim 15 , wherein the fumaric acid or ester or salt thereof is formulated for dissolving in stomach claim 15 , intestines claim 15 , or further distal in the gastrointestinal tract of the subject.18. The method of claim 15 , wherein the pharmaceutical composition is in the form of a capsule.19. A method of treating multiple sclerosis (MS) claim 15 , psoriasis claim 15 , a motor neuron disease claim 15 , a neurodegenerative disease ...

Подробнее
20-01-2022 дата публикации

Once Daily Formulations Of Tetracyclines

Номер: US20220016041A1
Принадлежит:

Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis. 1. An oral pharmaceutical composition containing a tetracycline , which at a once-daily dosage will give steady state blood levels of the tetracycline of a minimum of about 0.1 μg/ml and a maximum of about 1.0 μg/ml.2. The composition of claim 1 , which at a once-daily dosage will give steady state blood levels of the tetracycline of between about 0.3 μg/ml to about 0.8 μg/ml.3. The composition of claim 1 , wherein the tetracycline is doxycycline.47-. (canceled)8. The composition of claim 1 , which is a combination of a component containing a tetracycline in an immediate release (IR) formulation and a second component containing a tetracycline in a delayed release (DR) formulation claim 1 , wherein the ratio of IR to DR is from about 99:1 to about 70:30.9. The composition of claim 8 , wherein the tetracycline is doxycycline.10. The composition of claim 9 , wherein the ratio of immediate release component to delayed release component is from about 80:20 to about 70:30.11. The composition of claim 9 , wherein the ratio of immediate release component to delayed release component is 75:25.1217-. (canceled)18. An oral pharmaceutical dosage form containing between 25 and 50 mg. of a tetracycline.19. The dosage form of claim 18 , wherein the tetracycline is doxycycline.20. The dosage form of claim 19 , which contains about 40 mg. of doxycycline.21. The dosage form of claim 18 , which is in an immediate release formulation.22. The dosage form of claim 18 , which is a granule claim 18 , tablet claim 18 , pellet claim 18 , powder claim 18 , sachet claim 18 , capsule claim 18 , gel claim 18 , dispersion or suspension.2324-. (canceled)25. The dosage form of ...

Подробнее
20-01-2022 дата публикации

Pharmaceutical composition containing tamsulosin hydrochloride with excellent acid resistance and preparation method therefor

Номер: US20220016058A1
Принадлежит: Hanmi Pharmaceutical Co Ltd

Disclosed are an acid-resistant pharmaceutical composition including tamsulosin hydrochloride, and a method of preparing the same. The pharmaceutical composition is formulated into tablets by preparing core beads including tamsulosin hydrochloride as an active ingredient, coating the core beads with an entering coating solution including a specific amount of plasticizer, adding a post mixture portion including a buffer to adjust density and a lubricant to the enteric-coated core beads, and performing tableting. The enteric coating layer is not broken during the tableting process. Thus, the acid resistance of the pharmaceutical composition is maintained. The pharmaceutical composition can be easily formulated into tablets, ensures good uniformity of dosage unit, lowers dissolution rate of tamsulosin hydrochloride, has good acid resistance, and is stable not to exhibit signification decomposition of tamsulosin hydrochloride.

Подробнее
12-01-2017 дата публикации

Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and T2D

Номер: US20170007631A1
Принадлежит:

The invention provides pharmaceutical compositions, methods for the treatment of, and related diagnostics and computer-implementable systems that relate to, the treatment of a variety of metabolic syndromes, including hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states. In an additional aspect of the invention, compositions and methods of treatment are calibrated to the ileal brake response to surgical intervention e.g. RYGB, as both activate the ileal brake, which acts in the gastrointestinal tract and the liver of a mammal to control metabolic syndrome manifestations and thereby reverse or ameliorate the cardiovascular damage (atherosclerosis, hypertension, lipid accumulation, and the like) resulting from progression of metabolic syndrome. The net benefit is the potential to treat all of the common manifestations of metabolic syndrome, including T2D and obesity, with one medicament, which contains glucose as an activation agent for the ileal brake. The ileal brake is the controller for progression of metabolic syndrome, and both RYGB surgery and the oral formulation act beneficially on the metabolic syndrome manifestations via this pathway. Disclosed as well are combination medicaments that act synergistically on the ileal brake and the manifestations of metabolic syndrome. 1199-. (canceled)200. A method a treating the manifestations of metabolic syndrome in a human subject in need in a manner similar to Roux-en-Y gastric bypass (RYGB) surgery wherein said manifestations of metabolic syndrome include the following: a reduction of insulin resistance whereby blood glucose and blood insulin levels are normalized; a regulation of ileal brake associated immunological actions resulting in beneficial regulation of hepatic inflammation and fatty liver; a lowering of blood triglycerides , and hepatic glucose and triglycerides; reduction in abdominal obesity and a reduction in ...

Подробнее
11-01-2018 дата публикации

GASTRORETENTIVE EXTENDED RELEASE SUSPENSION COMPOSITIONS

Номер: US20180008539A1
Принадлежит: SUN PHARMACEUTICAL INDUSTRIES LIMITED

The present invention relates to a gastroretentive extended release suspension composition, wherein the composition is characterized by having no substantial change in the in-vitro dissolution release profile upon storage for at least seven days. The invention also relates to processes for the preparation of said gastroretentive extended release suspension compositions. 1. A gastroretentive extended release suspension composition comprising an active ingredient and a suspension base , wherein the composition is characterized by having no substantial change in the in-vitro dissolution release profile upon storage for at least seven days.2. The gastroretentive extended release suspension composition of claim 1 , wherein the active ingredient is in the form of multiple cores coated with a release-controlling polymer.3. The gastroretentive extended release suspension composition of claim 1 , wherein the composition is characterized by having an osmolality ratio of at least about 1.4. The gastroretentive extended release suspension composition of claim 1 , wherein the suspension base is responsible for creating a hypertonic environment.5. The gastroretentive extended release suspension composition of claim 1 , wherein the suspension base comprises an osmogent.6. The gastroretentive extended release suspension composition of claim 5 , wherein the suspension base further comprises a gel-forming agent and a gas-generating agent.7. The gastroretentive extended release suspension composition of claim 1 , wherein the composition is a suspension or a reconstituted powder for suspension.8. The gastroretentive extended release suspension composition of claim 2 , wherein active ingredient is layered onto an inert particle to form the core.9. The gastroretentive extended release suspension composition of claim 8 , wherein the inert particle is selected from the group comprising a non-pareil seed claim 8 , a microcrystalline cellulose sphere claim 8 , a dibasic calcium phosphate ...

Подробнее
11-01-2018 дата публикации

CONTROLLED RELEASE FORMULATIONS

Номер: US20180008544A1
Принадлежит:

The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval. 120.-. (canceled)21. An oral controlled release formulation , comprisinga plurality of substrates comprising a portion of an effective dose of methylphenidate or a pharmaceutically acceptable salt thereof in immediate release form,a hydrophobic material comprising an acrylic polymer coated onto the surface of said substrates in an amount sufficient to retard the release of said portion of the methylphenidate or a pharmaceutically acceptable salt thereof,an enteric coating applied over said hydrophobic coating to obtain enteric coated substrates, wherein said enteric coating is in an amount sufficient to substantially delay the release of said methylphenidate or a pharmaceutically acceptable salt thereof from said substrates until after said formulation passes through the stomach, wherein said enteric coating is derived from an aqueous dispersion comprising an acrylic/methacrylic copolymer, a plasticizer and a glidant,the formulation further comprising the remaining portion of the effective dose of the methylphenidate or pharmaceutically acceptable salt thereof in immediate release form, andwherein the formulation provides a maximum plasma concentration of methylphenidate at about 0.5 to about 2 hours after oral administration,and the duration of effect provided by the methylphenidate or pharmaceutically acceptable salt thereof contained in the formulation falls below effective plasma concentrations at about 10 to about 12 hours after the oral administration.22. The oral controlled release formulation of claim 21 , wherein said formulation comprises methylphenidate hydrochloride.23. The oral ...

Подробнее
14-01-2021 дата публикации

BETA-LACTAMASE FORMULATIONS AND USES THEREOF

Номер: US20210007994A1
Принадлежит:

The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided. 1. A modified-release formulation , comprising a beta-lactamase , wherein the formulation releases a substantial amount of the beta-lactamase in the GI tract.2. The modified-release formulation of claim 1 , wherein the beta-lactamase comprises an amino acid sequence having at least 95% identity with SEQ ID NO: 1.3. The formulation of any of the above claims claim 1 , wherein the beta-lactamase is substantially released in the small intestine.4. The formulation of any of the above claims claim 1 , wherein the beta-lactamase is substantially released in the large intestine.5. The formulation of any of the above claims claim 1 , wherein the formulation comprises a core particle claim 1 , a base coat over the core particle claim 1 , and wherein the base coat comprises the beta-lactamase.6. The formulation of claim 5 , wherein the core particle comprises sucrose.7. The formulation of any of the above claims claim 5 , wherein the formulation comprises a core particle claim 5 , and wherein the beta-lactamase is encapsulated within the core particle.8. The formulation of - claim 5 , wherein the formulation comprises a plurality of core particles.9. The formulation of any one of the above claims claim 5 , wherein the formulation further comprises a modified-release coating that is substantially stable in gastric fluid.10. The formulation of any one of the above claims claim 5 , wherein the formulation comprises a modified-release coating that is degraded by a microbial enzyme present in the gut flora.11. The formulation of any one of the above claims claim 5 , wherein the formulation comprises a modified-release coating having a solubility that is pH-dependent.12. ...

Подробнее
14-01-2021 дата публикации

METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING

Номер: US20210007996A1
Принадлежит: SOL-GEL TECHNOLOGIES LTD.

The invention relates to a process for coating a solid, water-insoluble particulate matter, with a metal oxide comprising: (a) contacting the solid, water-insoluble particulate matter with an ionic additive and an aqueous medium to obtain a dispersion of said particulate matter having positive charges on its surface; (b) subjecting the particulate matter to a coating procedure comprising precipitating a metal oxide salt onto the surface of the particulate matter to form a metal oxide layer thereon to thereby obtain particulate matter coated by a metal oxide coating layer; (c) repeating step (b) at least 4 more times; and (d) aging said coating layer. The invention further relates to particles comprising a particulate matter coated by a metal oxide layer, to a use of the particles for topical administration, and to a method for preventing, reducing, or eliminating pests at a locus, using the particles. 1. Particles comprising solid benzoyl peroxide particulate matter encapsulated by a metal oxide coating , wherein the metal oxide coating comprises four or more layers; whereinhe outermost portion of the metal oxide coating being substantially free of benzoyl peroxide; wherein the weight ratio of the metal oxide to said benzoyl peroxide, is in the range of 1:99 to 40:60;the coated particles having leaching of less than 5% w/w, of the benzoyl peroxide in the composition until administered to the skin;the coated particles release an effective amount of benzoyl peroxide when the composition is in contact with the surface; andthe time for releasing 50% w/w of the benzoyl peroxide being at least two-fold longer when in coated form than the time to dissolution of benzoyl peroxide particles of the same particle size diameter when in free form under identical conditions.2. The particles according to claim 1 , wherein said metal oxide coating has a thickness of 0.1-10 micron.3. Particles comprising solid benzoyl peroxide particulate matter encapsulated by a metal oxide coating ...

Подробнее
14-01-2021 дата публикации

Solid Carriers for Improved Delivery of Active Ingredients in Pharmaceutical Compositions

Номер: US20210008212A1
Автор: Patel Mahesh V.
Принадлежит: LIPOCINE INC.

The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents. 1. A pharmaceutical composition in the form of a solid carrier , said composition comprising ,at least two components selected from the group consisting of a pharmaceutical active ingredient; a hydrophilic surfactant comprising a hydrogenated castor oil, and a lipophilic component comprising a vegetable oil and further comprising a fatty acid,wherein the pharmaceutical active ingredient is testosterone undecanoate.27-. (canceled)8. The pharmaceutical composition of claim 1 , wherein the composition includes a hydrophilic surfactant and the hydrophilic surfactant represents 2.4% w/w to 76% w/w of the solid carrier.9. The pharmaceutical composition of claim 1 , wherein the composition includes hydrophilic surfactant and the hydrophilic surfactant 12.1% w/w to 76% w/w of the solid carrier.10. The pharmaceutical composition of claim 1 , wherein the composition is formulated for immediate release.11. The pharmaceutical composition of claim 1 , wherein the composition is formulated for pulsatile release claim 1 , ...

Подробнее
10-01-2019 дата публикации

STABLE ORALLY DISINTEGRATING PHARMACEUTICAL COMPOSITIONS

Номер: US20190008767A1
Принадлежит: Dexcel Pharma Technologies Ltd.

Described herein are stable orally disintegrating tablets containing a proton pump inhibitor, methods for making the same, and methods for treating subjects in need thereof. In particular, the orally disintegrating tablets are composed of a plurality of coated units admixed with a disintegrant that demonstrate decreased friability and increased hardness. 2. The tablet of claim 1 , wherein each core comprises an inert seed coated with an active ingredient coating comprising a proton pump inhibitor.3. The tablet of claim 2 , wherein the inert seed comprises a granule claim 2 , a pellet claim 2 , a bead claim 2 , or a powder.4. The tablet of claim 1 , wherein the proton pump inhibitor comprises omeprazole claim 1 , lansoprazole claim 1 , pantoprazole claim 1 , rabeprazole claim 1 , tenatoprazole claim 1 , ilaprazole or a mixture or combination thereof.5. The tablet of claim 1 , wherein each unit further comprises a subcoating between the plurality of cores and the enteric coating.6. The tablet of claim 5 , wherein the subcoating comprises one or more of hydroxypropyl methylcellulose claim 5 , hydroxypropyl cellulose claim 5 , polyvinylpyrrolidone claim 5 , polyethylene glycol claim 5 , polyvinyl alcohol or a mixture or combination thereof.7. The tablet of claim 1 , wherein the enteric coating comprises one or more of cellulose acetate phthalate (CAP) claim 1 , hydroxypropyl methylcellulose phthalate (HPMCP) claim 1 , hydroxypropyl methylcellulose acetate succinate (HPMCAS) claim 1 , polyvinyl acetate phthalate claim 1 , cellulose acetate trimellitate claim 1 , shellac claim 1 , polymethacrylic acid claim 1 , polymethyl methacrylate claim 1 , polyethyl methacrylate claim 1 , polyethyl acrylate or a mixture or combination thereof.8. The tablet of claim 1 , wherein the coating comprising a reverse enteric polymer comprises a (meth)acrylate polymer or copolymer.9. The tablet of claim 1 , wherein the reverse enteric polymer comprises a methyl methacrylate-butyl methacrylate ...

Подробнее
10-01-2019 дата публикации

Controlled Release Dosage Form for Once Daily Administration of Dimethyl Fumarate

Номер: US20190008768A1
Принадлежит: Biogen MA Inc.

A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof. 126-. (canceled)27. A mucoadhesive dosage form comprising an active pharmaceutical ingredient and one or more mucoadhesive polymers; wherein the active pharmaceutical ingredient is monomethyl fumarate , a compound that can be metabolized into monomethyl fumarate in vivo , a pharmaceutically acceptable salt thereof , or combinations thereof; and wherein the one or more mucoadhesive polymers comprises poly(vinyl pyrrolidone).28. The mucoadhesive dosage form of claim 27 , wherein administration of said mucoadhesive dosage form to a subject provides one or more of the following pharmacokinetic parameters: (a) a mean plasma MMF AUCranging from about 4.81 h·mg/L to about 11.2 h·mg/L; (b) a mean plasma MMF AUCranging from about 2.4 h·mg/L to about 5.5 h·mg/L; and (c) a mean AUCranging from about 2.4 h·mg/L to about 5.6 h·mg/L.29. The mucoadhesive dosage form of claim 27 , wherein upon administration of said mucoadhesive dosage form to a subject claim 27 , the active pharmaceutical ingredient is retained in the small intestine of the subject for at least 3 hours.30. The mucoadhesive dosage form ...

Подробнее
10-01-2019 дата публикации

MULTILAYERED PHARMACEUTICALLY ACTIVE COMPOUND-RELEASING MICROPARTICLES IN A LIQUID DOSAGE FORM

Номер: US20190008787A1
Принадлежит:

The present invention concerns controlled-release multilayer microparticle containing a pharmaceutically active compound, said microparticle being intended for oral administration or direct administration in the stomach in the form of a liquid pharmaceutical composition. 1. A controlled-release multilayer microparticle containing a pharmaceutically active compound , said microparticle being intended for oral administration or direct administration in the stomach in the form of a liquid pharmaceutical composition and said microparticle comprising:a core comprising the pharmaceutically active compound;a controlled-release intermediate coating layer;an outmost external protection coating layer surrounding the controlled-release intermediate coating layer and containing a mixture ofa) a hydrophilic gastro-soluble component which is insoluble in aqueous media at a pH of between 6.5 and 7.5, andb) a hydrophobic and/or insoluble component.2. The microparticle according to claim 1 , wherein the pharmaceutically active compound is an acid labile pharmaceutically active compound or an unstable pharmaceutically active compound in acidic conditions claim 1 , a pharmaceutically active compound which is aggressive for the gastric mucosa claim 1 , a pharmaceutically active compound whose therapeutical efficacy needs to be improved or prolonged with a sustained-release layer or a pharmaceutically active compound who needs to target a section of the gastro-intestinal tract other than the stomach.3. The microparticle according to claim 1 , wherein the controlled-release intermediate coating layer is a delayed release coating layer.4. The microparticle according to claim 1 , wherein the hydrophilic gastro-soluble component is a cationic synthetic or natural polymer.5. The microparticle according to claim 1 , wherein the hydrophobic and/or insoluble component is chosen from the group consisting of glycerides claim 1 , wax claim 1 , magnesium stearate claim 1 , fatty alcohol claim 1 , ...

Подробнее
08-01-2015 дата публикации

Escalating Dosing Regimen for Effecting Weight Loss and Treating Obesity

Номер: US20150010626A1
Принадлежит:

The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions. 1. A controlled release composition for treating obesity , diabetes or a related condition in a subject comprising:an effective amount of topiramate;microcrystalline cellulose; andmethylcellulose.2. The composition of claim 1 , wherein the topiramate claim 1 , the microcrystalline cellulose claim 1 , and the methylcellulose are present in a matrix core of a bead.3. The composition of claim 2 , wherein the matrix core is coated with ethyl cellulose.4. The composition of claim 3 , wherein the matrix core is further coated with polyvinyl pyrrolidone.5. The composition of claim 4 , wherein the bead is encapsulated into a capsule.6. The composition of claim 5 , wherein the capsule further comprises a sympathomimetic agent.7. The composition of claim 6 , wherein the sympathomimetic agent is phentermine.8. The composition of claim 7 , wherein the phentermine is coated onto a sugar sphere.9. The composition of claim 7 , wherein the phentermine is coated onto the controlled release topiramate beads.10. The composition of claim 7 , wherein the phentermine is in immediate release form.11. The composition of claim 7 , wherein the phentermine is in controlled release form.12. The composition of claim 6 , wherein the sympathomimetic agent is bupropion.13. The composition of claim 12 , wherein the bupropion is coated onto a sugar sphere.14. The composition of claim 12 , wherein the bupropion is coated onto the controlled release topiramate beads.15. The composition of claim 12 , wherein the bupropion is an immediate ...

Подробнее
09-01-2020 дата публикации

Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof

Номер: US20200009062A1
Принадлежит: Impax Laboratories LLC

The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.

Подробнее
09-01-2020 дата публикации

ORAL PHARMACEUTICAL COMPOSITION

Номер: US20200009218A1
Автор: Coulter Ivan
Принадлежит: Sublimity Therapeutics Limited

An oral composition comprising minicapsules wherein the minicapsules comprise one or more therapeutic prophylactic substances in a liquid, semi-liquid, or solid core. The minicapsules have release profiles to release the substance in an active form at one or more sites along the gastro-intestinal tract to maximise absorption and/or therapeutic efficiency. 191-. (canceled)92. A method for the treatment of inflammatory bowel disease , wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of an oral composition comprising minicapsules wherein the minicapsules comprise an active pharmaceutical in a liquid , semi-solid , or solid core , the minicapsules having release profiles to release the active pharmaceutical in an active form at one or more sites along the gastrointestinal tract; wherein the active pharmaceutical is selected from:an immunosuppressant;a hydroxylase inhibitor ora combination thereof.93. The method of claim 92 , wherein the inflammatory bowel disease is selected from ulcerative colitis or Crohn's disease.94. The method of claim 92 , wherein the active pharmaceutical is a hydroxylase inhibitor.95. The method of claim 94 , wherein the hydroxylase inhibitor is selected from a propyl hydroxylase inhibitor or an asparaginyl hydroxylase inhibitor.96. The method of wherein the active pharmaceutical is DMOG.97. The method of wherein the active pharmaceutical is hydralazine.98. The method of wherein the active pharmaceutical is FG4095.99. The method of claim 92 , wherein the minicapsules further comprise an excipient selected from an excipient to maximize permeability of the active pharmaceutical compound(s) in the colon claim 92 , an excipient to maximize solubility of the active pharmaceutical compound(s) in the colon claim 92 , and combinations thereof.100. The method of wherein the minicapsules comprise a gelling agent encapsulating the active pharmaceutical.101. The method of wherein the active ...

Подробнее
09-01-2020 дата публикации

PHARMACEUTICAL CYCLOSPORIN COMPOSITIONS

Номер: US20200009219A1
Автор: Coulter Ivan
Принадлежит: Sublimity Therapeutics Limited

An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases. 1. (canceled)2. A method of treating ulcerative colitis by administering to a subject a composition , the method comprising orally administering the composition , wherein the composition comprises cyclosporin in a solubilised liquid form in combination with a pharmaceutically acceptable carrier(s) or excipient(s) , wherein the cyclosporin and the pharmaceutically acceptable carrier(s) or excipient(s) are contained within a gelling agent and the composition comprises a modified release coating suitable to provide the release of the cyclosporin in the colon.3. The method of claim 2 , wherein the method further comprises administering to the subject any one or a combination of tacrolimus claim 2 , sirolimus claim 2 , EPA or DHA.4. The method of claim 3 , wherein the composition has a dissolution profile claim 3 , when tested in a U.S.P. Type II apparatus (paddles) at 37° C. and 50 rpm claim 3 , in pH 6.8 buffer as follows: 1 hour: less than or equal to about 20% drug released.5. The method of claim 4 , wherein at 4 hours: about 20% to about 35% drug released.6. The method of claim 5 , wherein at 6 hours: about 35% to about 50% drug released.7. The method of claim 6 , wherein at 12 hours: about 50% to about 60% drug released.8. The method of claim 7 , wherein at 16 hours: about 60% to about 75% drug released.9. The method of claim 8 , wherein at 24 hours from about 75% to about 100% drug released.10. The method of claim 2 , wherein the composition has a dissolution profile claim 2 , when tested in a U.S.P. Type II apparatus (paddles) at 37° C. and 50 rpm claim 2 , in pH 6.8 buffer as follows: 4 hours: about 30% to about 50% drug released.11. The ...

Подробнее
03-02-2022 дата публикации

Tamper Resistant Immediate Release Formulations

Номер: US20220031693A1
Принадлежит:

Disclosed in certain embodiments is an immediate release solid oral dosage form comprising a plurality of particles, each particle comprising: (i) a core comprising a first active agent; (ii) a coating comprising a second active agent layered over the core; and (iii) a material that is sensitive to acidic pH layered over the coated core; wherein the dosage form releases at least about 70% of the second active agent within 45 minutes as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at 50 rpm in 500 ml 0.1 N HCl at 37° C. 1. A method of treating pain comprising administering to a patient in need thereof , an immediate release solid oral dosage form comprising a plurality of particles , each particle comprising:(i) an active agent; and(ii) a material that is sensitive to acidic pH;wherein the dosage form releases at least about 70% of the active agent within 45 minutes as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at 50 rpm in 500 ml 0.1 N HCl at 37° C.2. The method of claim 1 , wherein the plurality of particles are dispersed in a matrix.3. The method of claim 2 , wherein the matrix comprises a gelling agent.4. The method of claim 2 , wherein the matrix comprises a disintegrant.5. The method of claim 2 , wherein the matrix comprises a filler.6. The method of claim 1 , wherein each particle comprises either (I) a core comprising the active agent and the material sensitive to acidic pH layered on the core; or (II) a core comprising a first active agent claim 1 , a coating comprising a second active agent layered over the core and a material that is sensitive to acidic pH layered over the coated core.7. The method of claim 6 , wherein the core comprises an inert excipient layered with the active agent.8. The method of claim 6 , wherein the core comprises the active agent dispersed in a pharmaceutically acceptable excipient.9. The method of claim 1 , wherein each particle comprises:(i) a core comprising an inert excipient; and(ii) a ...

Подробнее
03-02-2022 дата публикации

MODIFIED RELEASE DOXYCYCLINE COMPOSITION

Номер: US20220031714A1
Принадлежит:

Doxycycline formulations with a reduced food effect are disclosed. Particularly disclosed are modified release formulations which can be administered once a day and exhibit a reduced food effect. Methods of treating inflammatory conductions such as rosacea or inflammatory symptoms such as the papules and pustules of rosacea or acne vulgaris are also disclosed. 111-. (canceled)12. A method of treating inflammatory rosacea or an inflammatory symptom of either rosacea or acne vulgaris comprising administering to a human patient in need thereof a modified release oral composition comprising:(i) about 30 to less than about 50 mg of doxycycline, based on the equivalent weight of doxycycline base, wherein the doxycycline is in an amount of about 15-20% w/w;(ii) about 10-18% w/w of one or more water soluble and insoluble polymers; and(iii) about 1-20% w/w of one or more pharmaceutically acceptable excipients; [{'sub': 0', '30, '(a) average input rate of about 4 ng/hr/mL to about 15 ng/hr/mL during a time period of Tmin to Tmin, and'}, {'sub': 0', '60, '(b) average input rate of about 15 ng/hr/mL to about 40 ng/hr/mL during a time period of Tmin to Tmin.'}], 'wherein the composition is free of any immediate release component; and wherein the composition provides at least one of the following pharmacokinetic parameters13. The method according to claim 12 , wherein the doxycycline is an acid addition salt of doxycycline.14. The method according to claim 13 , wherein the acid addition salt of doxycycline is doxycycline hyclate.15. The method according to claim 14 , wherein the doxycycline hyclate is present in an amount of about 46 mg.16. The method according to claim 12 , wherein the composition exhibits a reduced food effect selected from the group consisting of an AUC of less than about 15% and a Cof less than about 40% upon oral administration to a human.17. The method according to claim 16 , wherein the composition exhibits a reduced food effect as a Cof less than about 35 ...

Подробнее
18-01-2018 дата публикации

USE OF MTOR INHIBITORS TO PREVENT AND REGRESS EDHESIONS AND FIBROSIS

Номер: US20180015074A1
Автор: KELLOGG Dean L.
Принадлежит:

Embodiments of the disclosure include preventing or reducing adhesion between two tissues and/or organs in an individual subjected to a procedure and/or preventing or reducing one or more keloids in an individual subjected to a procedure by providing to the individual an effective amount of a composition comprising one or more inhibitors of an mTOR pathway no earlier than about 4 days following the procedure. 1. A method ofa) preventing or reducing adhesion between two tissues and/or organs in an individual subjected to a procedure, and/orb) preventing or reducing one or more keloids in an individual subjected to a procedure;comprising the step of providing to the individual an effective amount of a composition comprising one or more inhibitors of an mTOR pathway no earlier than about 4 days following the procedure.2. The method of claim 1 , wherein the inhibitor of an mTOR pathway is rapamycin and/or a rapamycin analog.3. The method of claim 2 , wherein the rapamycin analog is selected from the group consisting of temsirolimus claim 2 , everolimus claim 2 , deforolimus claim 2 , CCI-779 claim 2 , curcumin claim 2 , Green tea extract standardised to 70% EGCG claim 2 , transresveratrol claim 2 , fisetin claim 2 , salicin extracted from white willow claim 2 , and a combination thereof.4. The method of claim 1 , wherein the inhibitor of the mTOR pathway is an ATP-competitive mTOR kinase inhibitor.5. The method of claim 4 , wherein the ATP-competitive mTOR kinase inhibitor is selected from the group consisting of AZD8055 claim 4 , Torin1 claim 4 , PP242 claim 4 , PP30 and a combination thereof.6. The method of any of - claim 4 , wherein the adhesions are between abdominal claim 4 , pelvic claim 4 , or thoracic organs and/or with the walls of the abdominal claim 4 , pelvic claim 4 , or thoracic cavities.7. The method of claim 6 , wherein the pelvic adhesions involve a reproductive organ claim 6 , the urinary bladder claim 6 , the pelvic colon claim 6 , and/or the rectum. ...

Подробнее
18-01-2018 дата публикации

COMPOSITIONS AND METHODS FOR TREATMENT IN PARKINSON'S DISEASE PATIENTS

Номер: US20180015080A1
Автор: AZHIR Ari
Принадлежит:

The invention provides dosage forms and methods for treating Parkinson's Disease, symptoms resulting from Parkinson's Disease, side effects resulting from treatment of Parkinson's Disease with other pharmaceutical agents, and reducing the progress of Parkinson's Disease. In various embodiments, the dosage forms and methods utilize nicotine and/or salts thereof for once daily administration resulting in four pulsatile releases following administration. 1. An oral pulsatile release dosage form for once-daily oral administration , said form comprising an effective amount of nicotine or a salt thereof for treatment of symptoms of Parkinson's Disease or symptoms associated with dopaminergic treatment of Parkinson's Disease or for delay in progression of Parkinson's Disease , wherein said form exhibits first , second , third , and fourth pulsatile releases of nicotine or salt thereof;wherein said first pulsatile release occurs with a maximum release within two hours of administration, said second pulsatile release occurs with a maximum release between five and seven hours following administration, said third pulsatile release occurs with a maximum release between eleven and thirteen hours following administration, and said fourth pulsatile release occurs with a maximum release between sixteen and twenty hours following administration; or wherein said first pulsatile release occurs with a maximum release between about two to four hours of administration, said second pulsatile release occurs with a maximum release between seven and nine hours following administration, said third pulsatile release occurs with a maximum release between thirteen and fifteen hours following administration, and said fourth pulsatile release occurs with a maximum release between eighteen and twenty-two hours following administration; orwherein said first pulsatile release occurs with a maximum release within two hours of entering the small intestine, said second pulsatile release occurs with a ...

Подробнее
18-01-2018 дата публикации

SITE SPECIFIC DOSING OF A BTK INHIBITOR

Номер: US20180015088A1
Принадлежит:

Disclosed herein are formulations and methods of site specific administration of Compound (I) or a pharmaceutically acceptable salt thereof. Compound (I) is a potent BTK inhibitor and hence can be useful for the treatment of diseases such as cancer, autoimmune, and inflammatory diseases. 1. A solid oral dosage form comprising:(i) 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile(Compound (I)) and/or a pharmaceutically acceptable salt thereof;(ii) means for release of Compound (I) and/or said pharmaceutically salt thereof in one or more mammalian intestinal sites chosen from the duodenum, jejunum, ileum, and colon; and(iii) a pharmaceutically acceptable excipient,wherein the average systemic bioavailability of Compound (I) as measured by plasma AUC resulting from administration of said solid oral dosage form is from about 150% to about 4000% of the average systemic bioavailability of Compound (I) as measured by plasma AUC resulting from administration of an immediate release dosage form having an equivalent amount of said Compound (I) and/or said pharmaceutically acceptable salt thereof.2. The solid oral dosage form of claim 1 , wherein:not more than about 10% of the AUC resulting from administration of said solid oral dosage form is contributed within about 1.5 to about 2 hours after dosing when the solid oral dosage form is administered to a mammal in the fasted state.3. A solid oral dosage form comprising:(i) 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile(Compound (I)) and/or a pharmaceutically acceptable salt thereof;(ii) means for release of Compound (I) and/or said pharmaceutically salt thereof in one or more mammalian intestinal sites chosen from the jejunum, ileum, and colon; and(iii) a pharmaceutically acceptable excipient,wherein the average ...

Подробнее
17-01-2019 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20190015341A1
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A method of treating pain comprising administering to a patient in need thereof an abuse deterrent controlled release oral dosage form comprising:a matrix comprising oxycodone or a pharmaceutically acceptable salt thereof, a copolymer comprising trimethyl ammonioethyl methacrylate, and a gelling agent comprising polyethylene oxide and microcrystalline cellulose; anda coating over the matrix, the coating comprising a mixture comprising an aminoalkyl methacrylate copolymer, sodium lauryl sulfate, talc and simethicone;wherein the oxycodone or pharmaceutically acceptable salt thereof is the sole active agent in the dosage form,the abuse deterrent dosage form forming a gel when subjected to tampering comprising dissolution in from about 0.5 ml to about 10 ml of an aqueous liquid;the dosage form having a ratio of gelling agent to oxycodone or pharmaceutically acceptable salt thereof from about 8:1 to about 1:8; andthe dosage form providing a therapeutic effect for about 12 hours or longer when orally administered to a human patient.42. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 10 cP or more to the gel.43. The method of claim 41 , wherein the gelling agent is in an effective amount to impart a viscosity of about 60 cP or more to the ...

Подробнее
17-01-2019 дата публикации

PREMIXTURE AND PHARMACEUTICAL COMPOSITION FOR THE ORAL ADMINISTRATION OF MEMANTINE AS A PERMANENT SUSPENSION OR ONE PREPARED PRIOR TO ADMINISTERING TO THE PATIENT AND OPTIONALLY BY ENTERAL FEEDING TUBE AND CORRESPONDING PROCEDURES

Номер: US20190015357A1
Автор: Atilio Los Mario
Принадлежит:

Pharmaceutical composition of memantine for administering orally which comprises a premixture comprising: 1. A premixture of a pharmaceutical composition of memantine for administering orally characterized in that it comprises: i.1) a first coating of polyvinylpyrrolidone, and', 'i.2) a second coating comprising between 80 and 95% w/w total of the coating, of the cationic copolymer coating of dimethylaminoethyl methacrylate, butyl methacrylate and methyl methacrylate and between 5 and 20% w/w total of the coating, of the coating of magnesium stearate;, 'i) between 74 and 85% w/w total of the premixture of a granulate of pellets comprising memantine between 10 and 15% w/w total of the premixture; pregelatinised corn starch, silicon dioxide and microcrystalline cellulose, coated withii) between 4 and 7% w/w total of the premixture of sucralose; andiii) between 11 and 19% w/w total of the premixture of essences;wherein all the components have a particle size smaller than 710 microns,wherein, in the presence of water, 90% of the particles in suspension have an average diameter less than 170 microns,wherein, according to the dissolution assay in the Japanese Pharmacopea XV, the dissolution of memantine at a pH similar to the pH in the buccal cavity, at 15 seconds is less than 5%, at 30 seconds is lower than 10%, and at 60 seconds is less than 20%.2. The premixture according to claim 1 , characterized in that comprises:i) between 4 and 7% w/w total of the premixture of sucralose;ii) between 4 and 7% w/w total of the premixture of peppermint essence; andiii) between 7 and 12% w/w total of the premixture of lemon essence.3. The premixture according to claim 2 , characterized in that it comprises:i) between 5.0 and 5.5% w/w total of the premixture sucralose;ii) between 5.5 and 6.0%, w/w total of the premixture of peppermint essence; andiii) between 10.5 and 11.5% w/w total of the premixture of lemon essence.4. The premixture according to claim 1 , characterized in that it ...

Подробнее
16-01-2020 дата публикации

LAYERED PARTICLES AND PROCESSES THEREOF

Номер: US20200016562A1
Автор: PANAGIOTOU Thomai
Принадлежит:

Process for the preparation of layered particles are provided. Layered particles prepared by such processes are also provided 1116-. (canceled)117. A process for the preparation of layered particles comprising: (i) introducing one or more core particles into a first liquid carrier;', '(ii) mixing the one or more core particles in the first liquid carrier to form a first mixture;', '(iii) optionally, homogenizing the first mixture; and', '(iv) introducing one or more reactants into the first mixture;, '(a) forming a first liquid stream comprising (i) introducing one or more reactants into a second liquid carrier;', '(ii) mixing the one or more reactants in the second liquid carrier to form a second mixture; and', '(iii) optionally, homogenizing the second mixture;, '(b) forming a second liquid stream comprising(c) continuously pumping the first liquid stream into a first port of a multi-port mixing device, wherein the first liquid stream is pumped into the mixing device at a fraction of the flow rate of the mixing device;(d) continuously pumping the second liquid stream into a second port of the multi-port mixing device; and{'sup': 3', '10, '(e) mixing the first liquid stream and the second liquid stream inside the mixing device for an effective period of time to form a layer on the one or more core particles, wherein the mixing device is capable of producing an average energy rate per kilogram of the mixture of liquid streams of from about 10to about 10W/kg.'}118. The process of claim 117 , wherein step (a)(iv) further comprises introducing one or more surfactants into the first mixture.119. The process of claim 117 , wherein step (b)(i) further comprises introducing one or more surfactants into the second liquid carrier.120. The process of claim 117 , wherein step (a) further comprises washing the one or more core particles.121. The process of claim 117 , wherein the effective period of time is from about 1 microsecond to about 1 hour.122. The process of claim 120 ...

Подробнее
28-01-2016 дата публикации

L-Menthol Dosage Forms Having A Proteinaceous Coating For Enhanced Storage Stability

Номер: US20160022597A1
Автор: HASSAN FRED, SHAH Syed M.
Принадлежит:

A storage stable L-menthol composition including a tablet, caplet, capsule, or sachet dosage form has therein a core containing crystalline L-menthol and at least one pharmaceutical excipient. A proteinaceous coating of a continuous film of proteinaceous material is over the core. The film is effective to substantially prevent the crystalline L-menthol from volatilizing and leaving the core when stored at a temperature of 40 degrees C. and 75% relative humidity from between 1 day to 30 days. The dosage form contains an effective amount of the crystalline L-menthol for treating a gastrointestinal disorder. 1. A storage stable L-menthol composition comprising a tablet , caplet , capsule , or sachet dosage form having:a core containing crystalline L-menthol and at least one pharmaceutical excipient; anda proteinaceous coating of a continuous film of proteinaceous material over the core forming a proteinaceous coated core, the film being effective to substantially prevent the crystalline L-menthol from volatilizing and leaving the core when stored at a temperature of 40 degrees C. and 75% relative humidity from between 1 day to 30 days;wherein the dosage form contains an effective amount of the crystalline L-menthol for treating a gastrointestinal disorder.2. The storage stable L-menthol composition of claim 1 , wherein the crystalline L-menthol is in the form of a polycrystalline powder.3. The storage stable L-menthol composition of claim 1 , wherein the proteinaceous material includes gelatin.4. The storage stable L-menthol composition of claim 1 , wherein the proteinaceous material includes acid bone gelatin.5. The storage stable L-menthol composition of claim 1 , wherein the tablet claim 1 , caplet claim 1 , capsule claim 1 , or sachet dosage form also has an enteric coating over the proteinaceous coated core.6. The storage stable L-menthol composition of claim 5 , wherein the enteric coating comprises a methacrylic acid based material.7. The storage stable L- ...

Подробнее
26-01-2017 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20170020864A1

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Подробнее
26-01-2017 дата публикации

Composition Comprising a Therapeutic Agent and a Respiratory Stimulant and Methods for the Use Thereof

Номер: US20170020885A1
Автор: Hsu John
Принадлежит:

The present disclosure provides a safe method for anesthesia or the treatment of pain by safely administering an amount of active agent to a patient while reducing the incidence or severity of suppressed respiration. The present disclosure provides a pharmaceutical composition comprising a therapeutic agent and a chemoreceptor respiratory stimulant. In one aspect, the compositions oppose effects of respiratory suppressants by combining a chemoreceptor respiratory stimulant with an opioid receptor agonist or other respiratory-depressing drug. The combination of the two chemical agents, that is, the therapeutic agent and the respiratory stimulant, may be herein described as the “drugs.” The present compositions may be used to treat acute and chronic pain, sleep apnea, and other conditions, leaving only non-lethal side effects. 1. A pharmaceutical composition comprising a therapeutic agent and a respiratory stimulant.2. The pharmaceutical composition of claim 1 , wherein the therapeutic agent is an analgesic claim 1 , a benzodiazepine claim 1 , barbiturate claim 1 , an antihistamine claim 1 , or any combination thereof.3. The pharmaceutical composition of claim 2 , wherein the analgesic is an opioid receptor agonist or a non-steroidal anti-inflammatory agent.4. The pharmaceutical composition of claim 3 , wherein the opioid receptor agonist is an opioid mu receptor agonist.5. The pharmaceutical composition of claim 4 , wherein the opioid mu receptor agonist is selected from the group consisting of DAMGO ([D-Ala2 claim 4 , NMe-Phe4 claim 4 , Gly-ol5]-enkephalin) claim 4 , Endomorphin-1 (Endomorphin-1 TyrPro-Trp-Phe-NH2) claim 4 , Endomorphin-2 (Tyr-Pro-Phe-Phe-NH2) claim 4 , Fenanyl citrate (N-Phenyl-N-[1(2-phenylethyl)-4-piperidinyl]propanamide citrate) claim 4 , loperamide hydrochloride (4-(4Chlorophenyl)-4-hydroxy-N claim 4 , N-dimethyl-α claim 4 ,α-diphenyl-1-piperidinebutanamide hydrochloride) claim 4 , metazinol hydrochloride (3-(3-Ethylhexahydro-1-methyl-1 H- ...

Подробнее
26-01-2017 дата публикации

CONTROL RELEASE OF FAT SOLUABLE ANTIOXIDANTS FROM AN ORAL FORMULATION AND METHOD

Номер: US20170020908A1
Принадлежит:

Oral formulation of particles made of an agglomeration of a plurality of seed granules or a single seed granule both surrounded by three layers and an outer gel coating. The seed granules are made of calcium carbonate with microscopic fissures. Disposed inside the fissures and in the interstitial spaces of the agglomerate seed granules are microscopic particles of alkali metal salts and other ions. Coating the agglomerate or single seed granules is an alkaline-resistant first layer made of microcrystalline cellulose and croscarmellose sodium that binds and protects the surrounding second layer. Surrounding the second layer is a third layer made of alkaline earth metal salt particles holding alkali metal hydroxide ions within a polysaccharide or polymer gel. Surrounding the third layer is at least one outer gel layer. The fourth and third layers dissolve in a low pH environment and release the fat soluble antioxidant and ions in the seed granule fissures. 1. An oral formulation for the controlled release of fat soluble antioxidants made up of particles each particle comprising:a. seed granules each made of calcium carbonate with microscopic fissures and interstitial spaces formed therein, disposed inside the microscopic fissures and interstitial spaces are microscopic particles of alkali metal salt, alkali metal hydroxide or other ions;b. a first layer made of microcrystal line cellulose and croscarmellose sodium surrounding the outside surface of said seed granules;c. a second layer comprising a mixture of a fat soluble antioxidant and polysaccharide or polypeptide binder or polymer gel get;d. a third layer surrounding said second layer, said third layer made of microscopic alkaline earth metal salt particles mixed with alkali metal hydroxide, microcrystalline cellulose, croscarmellose sodium binders, and a polysaccharide gel or polymer gel; and,e. at least one harden outer gel layer surrounding said third layer.2. The oral formulation claim 1 , as recited in claim ...

Подробнее
25-01-2018 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20180021262A1
Принадлежит:

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. 140-. (canceled)41. A solvent system comprising:(a) a solvent; and (i) an opioid analgesic in an effective amount to provide an analgesic effect upon oral administration;', '(ii) an emulsifier;', '(iii) a fatty acid ester;', '(iv) a cellulosic polymer; and', '(v) silicon dioxide., '(b) a solute comprising42. The solvent system of claim 41 , having a ratio of emulsifier to opioid analgesic from about 15:1 to about 1:1 by weight.43. The solvent system of claim 42 , wherein the ratio of emulsifier to opioid analgesic is from about 8:1 to about 1:1 by weight.44. The solvent system of claim 42 , wherein the ratio of emulsifier to opioid analgesic is from about 8:1 to about 2:1 by weight.45. The solvent system of claim 42 , wherein the ratio of emulsifier to opioid analgesic is from about 8:1 to about 5:1 by weight.46. The solvent system of claim 41 , wherein the cellulosic polymer is hydroxyethylcellulose.47. The solvent system of claim 41 , further comprising cellulose acetate butyrate.48. The solvent system of claim 41 , wherein the solvent system comprises triacetin.49. The solvent system of claim 41 , further comprising a surfactant.50. The solvent system of claim 41 , wherein the solvent system comprises triacetin and a surfactant.51. The solvent system of claim 41 , wherein the opioid analgesic comprises ...

Подробнее
25-01-2018 дата публикации

Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent

Номер: US20180021330A1

Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.

Подробнее
10-02-2022 дата публикации

Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders

Номер: US20220040127A1
Принадлежит: Thiogenesis Therapeutics Inc

The invention features compositions, methods, and kits containing (i) one or more cysteamine precursor compounds convertible to cysteamine in vivo, and (ii) optionally agents to enhance that conversion, formulated to produce a spectrum of pharmacokinetic profiles of cysteamine that can be tailored to individual patients and diseases. The invention also features varying modes of administration of the therapeutic substances in the treatment of cystinosis and other cysteamine sensitive disorders. In particular, formulations combining active ingredient(s) with pharmaceutical excipients that permit sustained cysteamine plasma concentrations are featured.

Подробнее
22-01-2015 дата публикации

Pharmaceutical Compositions for the Deterrence and/or Prevention of Abuse

Номер: US20150024058A1
Принадлежит:

Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. 179-. (canceled)80. A composition comprising a plurality of multi-layer pellets comprising:a. a water-soluble core;b. an opioid antagonist comprising layer coating the core, wherein the opioid antagonist is naltrexone or a pharmaceutically acceptable salt thereof;c. a sequestering polymer layer coating the opioid antagonist comprising layer;d. an opioid agonist wherein the opioid agonist is selected from the group consisting of morphine, oxycodone, hydrocodone, hydromorphone dihydrocodeine, codeine, dihydromorphine, buprenorphine, salts of these molecules, and combinations thereof; and 'wherein the sequestering polymer layer comprises copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups, a surfactant in an amount from 1.6% to 6.3% of the copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups on a weight-to-weight basis,', 'e. a controlled release layer coating the opioid agonist;'}81. The composition of claim 80 , wherein the surfactant is selected from the group consisting of sodium lauryl sulfate claim 80 , sodium docusate claim 80 , dioctyl sodium sulphosuccinate claim 80 , sodium lauryl sarcosinate claim 80 , sodium methyl cocyl taurate claim 80 , magnesium lauryl sulfate claim 80 , dioctyl sodium sulfosuccinate claim 80 , sodium dodecylbenzene sulfonate claim 80 , and combinations thereof.82. The composition of claim 81 , wherein the surfactant is sodium lauryl sulfate.83. The composition of claim 80 , wherein the opioid agonist is morphine sulfate. This application is a ...

Подробнее
24-01-2019 дата публикации

Enteric coated oral pharmaceutical preparation comprising dimethyl fumarate

Номер: US20190022014A1
Принадлежит: ZAKLADY FARMACEUTYCZNE POLPHARMA SA

The present invention relates to an enteric coated oral pharmaceutical preparation in the form of a granulate, a pellet or a mini-tablet comprising dimethyl fumarate and having at least two coating layers, i.e. at least one inner enteric coating layer and an outer coating formed by applying a suspension comprising silicon dioxide on the at least one inner enteric coating layer. The invention relates also to the process for obtaining the enteric coated oral preparation of the present invention and to use of the preparation in the treatment of multiple sclerosis.

Подробнее
24-01-2019 дата публикации

INGESTIBLE MEDICAL DELIVERY DEVICES

Номер: US20190022015A1
Автор: FIRST Eric, Widom David
Принадлежит: ALCRESTA THERAPEUTICS, INC.

Exemplary embodiments of the disclosure may be drawn to ingestible delivery devices. An ingestible delivery device may include a first compartment and a second compartment. A lipase may be contained within the first compartment, and a fat may be contained within the second compartment. The first compartment may be sealed from the second compartment prior to exposure to a trigger, preventing the lipase and the fat from contacting each other, and at least one of the first compartment or the second compartment may at least partially rupture upon exposure to the trigger, allowing the lipase and the fat to contact each other. 1. An ingestible delivery device comprising:a first compartment;a second compartment;a lipase contained within the first compartment; anda fat contained within the second compartment;wherein the first compartment is sealed from the second compartment prior to exposure to a trigger, preventing the lipase and the fat from contacting each other, and wherein at least one of the first compartment or the second compartment at least partially ruptures upon exposure to the trigger, allowing the lipase and the fat to contact each other.2. The device of claim 1 , further comprising an exterior layer surrounding the first compartment and the second compartment.3. The device of claim 1 , further comprising a third compartment and at least one of a protein claim 1 , a protease claim 1 , a carbohydrate claim 1 , or an amylase contained within the third compartment.4. The device of claim 3 , further comprising a fourth compartment and at least one of a protein claim 3 , a protease claim 3 , a carbohydrate claim 3 , or an amylase contained within the fourth compartment.5. The device of claim 1 , wherein the first compartment is contained within the second compartment.6. The device of claim 1 , wherein the fat includes at least one of a structured lipid claim 1 , a short-chain fatty acid claim 1 , a medium-chain fatty acid claim 1 , or a long-chain fatty acid.7. The ...

Подробнее
23-01-2020 дата публикации

Compositions of midodrine and methods of using the same

Номер: US20200022919A1
Принадлежит: Xenamed Corp

This disclosure provides pharmaceutical compositions comprising midodrine, a pharmaceutically acceptable salt thereof, desglymidodrine, a pharmaceutically acceptable salt thereof, or a combination therefore that can be administered to a human subject in need thereof in a supine position. The disclosure also provides pharmaceutical compositions which can be administered once-a-day. This disclosure further provides pharmaceutical compositions comprising an extended release composition and providing a delayed release period between about 30 min to about 12 hours.

Подробнее
23-01-2020 дата публикации

SECNIDAZOLE FOR USE IN THE TREATMENT OF BACTERIAL VAGINOSIS

Номер: US20200022958A1
Принадлежит: SYMBIOMIX THERAPEUTICS, LLC

Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV). 152.-. (canceled)53. A single dose pharmaceutical composition for treating bacterial vaginosis in a subject in need thereof comprising a microgranule formulation having a therapeutically effective amount of secnidazole , the microgranule formulation comprising a plurality of microgranules , wherein the therapeutically effective amount of secnidazole is an amount of secindazole that exhibits a time to drug elimination half-life (t) of about 11.3 hours to about 20.4 hours in the subject , wherein the single dose pharmaceutical composition is for oral administration , and wherein the secnidazole is the sole drug in the microgranule formulation.54. The single dose pharmaceutical composition of claim 53 , wherein each microgranule comprises at least one compound selected from a group consisting of a sugar sphere claim 53 , povidone claim 53 , polyethylene glycol claim 53 , ethyl acrylate methyl methacrylate copolymer claim 53 , and talc.55. The single dose of pharmaceutical composition of claim 53 , wherein each microgranule comprises a sugar sphere core and an outer layer on the sugar sphere core claim 53 , the outer layer comprising secnidazole.56. The single dose pharmaceutical composition of claim 53 , wherein the subject is a female.57. The single dose pharmaceutical composition of claim 53 , wherein the subject is a pregnant female.58. The single dose pharmaceutical composition of claim 53 , wherein the therapeutically effective amount of secnidazole is 2 grams.59. The single dose pharmaceutical composition of claim 53 , wherein the single dose pharmaceutical composition is packaged in a single dose unit pouch or sachet.60. The single dose pharmaceutical composition of claim 53 , wherein the microgranule formulation is administered on the same day as a therapeutically effective amount of an additional compound selected from ...

Подробнее
28-01-2021 дата публикации

Crystal modifications of odevixibat

Номер: US20210024475A1
Принадлежит: ALBIREO AB

The present invention relates to crystal modifications of 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N—{(R)-α-[N—((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine (odevixibat), more specifically crystal modifications 1 and 2 of odevixibat. The invention also relates to a process for the preparation of crystal modification 1 of odevixibat, to a pharmaceutical composition comprising crystal modification 1, and to the use of this crystal modification in the treatment of various conditions as described herein.

Подробнее
04-02-2016 дата публикации

COMPOSITION FOR MANUFACTURING ORALLY DISINTEGRATING DOSAGE FORM TO PROTECT COATING LAYER OF ACTIVE SUBSTANCE

Номер: US20160030357A1
Принадлежит:

The present invention relates to a method of manufacturing an orally disintegrating dosage form which masks a bitter or unpleasant taste. A composition including a ratio of excipients and a coated active substance prevents a coating layer on the active substance from being destroyed during manufacture. 116-. (canceled)17. A method of manufacturing an orally disintegrating dosage form ,comprising applying pressure to a mixture of particles comprising particles of a coated active substance, particles of a buffer having lower hardness than the particles of the coated active substance, and particles of a shield having higher hardness and a larger particle size than the particles of the coated active substance, wherein the pressure is sufficient to fracture the buffer particles but not the active substance particles.18. The method of claim 17 , wherein the orally disintegrating dosage form is a tablet.19. The method of claim 17 , wherein prior to applying said pressure the hardness of the buffer particles is 0.1 to less than 1 times as high as the hardness of the coated active substance particles claim 17 , and the hardness of the shield particles is greater than 1 and less than or equal to 20 times as high as the hardness of the coated active substance particles.20. The method of claim 19 , wherein prior to applying said pressure the hardness of the buffer particles is 0.1 to 0.7 times as high as the hardness of the coated active substance particles claim 19 , and the hardness of the shield particles is 4 to 15 times as high as the hardness of the coated active substance particles.21. The method of claim 17 , wherein prior to applying said pressure the coated active substance particles have a particle diameter in the range of 0.1 to 1000 μm claim 17 , the buffer particles have a particle diameter 0.1 to 10 times as large as the particle diameter of the coated active substance particles claim 17 , and the shield particles have a particle size greater than 1 and less than ...

Подробнее
04-02-2016 дата публикации

Compositions and methods for treatment in parkinson's disease patients

Номер: US20160030412A1
Автор: Ari AZHIR
Принадлежит: Ari AZHIR

The invention provides dosage forms and methods for treating Parkinson's Disease, symptoms resulting from Parkinson's Disease, side effects resulting from treatment of Parkinson's Disease with other pharmaceutical agents, and reducing the progress of Parkinson's Disease. In various embodiments, the dosage forms and methods utilize nicotine and/or salts thereof for once daily administration resulting in four pulsatile releases following administration.

Подробнее
24-04-2014 дата публикации

GASTRORESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN

Номер: US20140112987A1
Принадлежит: Alfa Wassermann S.P.A.

The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease. 117-. (canceled)18. A gastroresistant rifaximin microgranule comprising rifaximin coated with a polymer insoluble at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5.19. The gastroresistant rifaximin microgranule of claim 18 , wherein the microgranule is coated with the polymer such that the rifaximin is retained in the microgranules at pH lower than 4.0 and is released at pH higher than 5.0.20. The gastroresistant rifaximin microgranule of claim 18 , wherein the gastroresistant rifaximin microgranule has a diameter from between about 1 micron to about 900 microns.21. The gastroresistant rifaximin microgranule of claim 18 , wherein the gastroresistant rifaximin microgranule has a diameter from between about 10 micron to about 500 microns.22. The gastroresistant rifaximin microgranule of claim 18 , wherein the polymer is selected from cellulose acetate phthalate claim 18 , hydroxypropylcellulose acetate phthalate claim 18 , polyvinyl acetate phthalate and copolymers of methacrylic acid.23. The gastroresistant rifaximin microgranule of claim 18 , wherein the polymer is selected from methacrylic acid ethylacrylate copolymer (1:1) claim 18 , methacrylic acid methylmethacrylate copolymer (1:2) and combinations thereof.24. The gastroresistant rifaximin microgranule of claim 18 , wherein the amount of gastrointestinal polymers is between about 5% and about 75% by weight in respect to the total weight of the microgranule.25. The gastroresistant rifaximin microgranule of claim 18 , wherein the gastroresistant rifaximin microgranule is ...

Подробнее
29-01-2015 дата публикации

Tamper Resistant Immediate Release Formulations

Номер: US20150030677A1
Принадлежит: Rhodes Pharmaeuticals LP

Disclosed is an immediate release solid oral dosage form comprising (i) an active agent; and (ii) a material that is sensitive to acidic pH;

Подробнее
17-02-2022 дата публикации

METHODS AND COMPOSITIONS FOR TREATING HYPERHIDROSIS

Номер: US20220047558A1
Автор: III Benjamin F., McGraw
Принадлежит:

Aspects of the disclosure include methods for treating hyperhidrosis in a subject with a composition including a muscarinic antagonist and a muscarinic agonist. In practicing methods according to certain embodiments, a therapeutically effective amount of a composition including a muscarinic antagonist or a pharmaceutically acceptable salt thereof and a muscarinic agonist or a pharmaceutically acceptable salt thereof is administered to a subject and is sufficient to reduce hyperhidrosis in the subject and to reduce a dry mouth side effect of the muscarinic antagonist. Compositions for practicing the subject methods are also described as well as dose units containing one or more of the subject compositions. 1. A method of treating hyperhidrosis in a subject in need thereof , the method comprising:orally administering to the subject a single unit dose of a therapeutically effective amount of a composition comprisinga plurality of immediate release beads of oxybutynin, or a pharmaceutically acceptable salt thereof, wherein each oxybutynin bead comprises: a core, and a first layer comprising oxybutynin, or a pharmaceutically acceptable salt thereof, positioned over the core, anda plurality of delayed-immediate release beads of pilocarpine, or a pharmaceutically acceptable salt thereof, wherein each pilocarpine bead comprises: a core, a first layer comprising pilocarpine, or a pharmaceutically acceptable salt thereof, positioned over the core, and a second layer comprising at least one polymer positioned over the first layer, andwherein the single unit dose is administered to a subject for a first dosage interval and a second dosage interval.2. The method according to claim 1 , wherein a time period for the first dosage interval is selected from a group consisting of 1 day or longer claim 1 , 2 days or longer claim 1 , 3 days or longer claim 1 , 5 days or longer claim 1 , 7 days or longer claim 1 , and 10 days or longer.3. The method according to claim 1 , wherein a time ...

Подробнее
31-01-2019 дата публикации

PHARMACEUTICAL COMPOSITIONS

Номер: US20190029964A1
Принадлежит:

Pharmaceutical compositions and methods are provided to treat headache, headache-associated symptoms, photophobia, or adverse effects associated with the headache. Also provided herein are small smooth particulates comprising a 5HTreceptor agonist. Compositions for oral administration are described herein wherein the compositions comprise a combination of active agents, such as a 5HTreceptor agonist and one or more antiemetics. 1. A method for treating a headache or photophobia in a subject in need thereof , comprising administering to the subject a pharmaceutical composition , an oral dosage thereof , and a capsule thereof , wherein the pharmaceutical composition comprises:{'sub': 1B/1D', '1B/1D, 'a plurality of first particulates, wherein each first particulate comprises a 5HTreceptor agonist that comprises from about 35 mg to about 140 mg of sumatriptan or a pharmaceutical acceptable salt thereof, wherein: (a) each first particulate has an average diameter of less than about 500 μm; or (b) each first particulate comprises from about 55% to about 65% of the 5HTreceptor agonist (w/w); and'} (i) a core; and', '(ii) a layer enclosing the core, wherein said layer comprises an antiemetic., 'a plurality of second particulates, wherein each second particulate comprises2. The method of claim 1 , wherein the 5HTreceptor agonist comprises the pharmaceutical acceptable salt of sumatriptan that is sumatriptan succinate.3. The method of claim 1 , wherein the method treats a headache that is a migraine headache.4. The method of claim 1 , wherein the treatment is acute or prophylactic.5. The method of claim 1 , wherein the administering treats a light sensitivity.6. The method of claim 1 , wherein the administering treats nausea associated with a headache or vomiting associated with a headache.7. The method of claim 1 , wherein the administering occurs one claim 1 , two claim 1 , or three times daily.8. The method of claim 1 , wherein the administering occurs about every 4 to ...

Подробнее
31-01-2019 дата публикации

Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral Administration

Номер: US20190029967A1
Принадлежит:

Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug. 1. A pharmaceutical composition comprising linaclotide and a pharmaceutically acceptable excipient , wherein the chromatographic purity of the linaclotide decreases by less than 10% after (a) 18 months of storage of the pharmaceutical composition at 25° C. at 60% relative humidity in a sealed container containing a desiccant or (b) 6 months of storage of the pharmaceutical composition at 40° C. at 75% relative humidity in a sealed container containing a desiccant.2. The pharmaceutical composition according to claim 1 , wherein the chromatographic purity of the linaclotide decreases by less than 9% claim 1 , 8% claim 1 , 7% claim 1 , 6% claim 1 , 5% claim 1 , or 4% after (a) 18 months of storage of the pharmaceutical composition at 25° C. at 60% relative humidity in a sealed container containing a desiccant or (b) 6 months of storage of the pharmaceutical composition at 40° C. at 75% relative humidity in a sealed container containing a desiccant.3. A unit dosage form of a pharmaceutical composition comprising linaclotide and a pharmaceutically acceptable excipient claim 1 , wherein the chromatographic purity of the linaclotide decreases by less than 10% after (a) 18 months of storage of the unit dosage form at 25° C. at 60% relative humidity in a sealed container containing a desiccant or (b) 6 months of storage of the unit dosage form at 40° C. at 75% relative humidity in a sealed container containing a desiccant.4. The unit dosage form according to claim 3 , ...

Подробнее
31-01-2019 дата публикации

MODIFIED RELEASE FORMULATION OF LACOSAMIDE

Номер: US20190029968A1
Принадлежит: Lupin Limited

The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cto Cpeak to trough variation over a period of at least 12 hrs. 114.-. (canceled)15. A modified release formulation comprising lacosamide and modified release polymer.16. The modified release formulation of claim 15 , wherein the modified release polymer is selected from the group consisting of hydrophilic polymer claim 15 , hydrophobic polymer claim 15 , wax; and mixtures thereof.17. The modified release formulation of claim 16 , wherein the hydrophilic polymer is selected from the group consisting of cellulose derivatives such as methyl cellulose claim 16 , hydroxypropyl methylcellulose claim 16 , hydroxyethyl cellulose claim 16 , hydroxypropyl cellulose claim 16 , hydroxyethyl methylcellulose claim 16 , carboxymethylcellulose and sodium carboxymethylcellulose; vinyl pyrrolidone polymers such as polyvinylpyrrolidone and copolymers of vinyl pyrrolidone and vinyl acetate; polysaccharides; gums of plant claim 16 , animal claim 16 , mineral or synthetic origin; polysaccharide such as alginic acid derivatives; chitosan claim 16 , gellan and xanthan gum; alkylene oxide such as polyethylene oxide; and mixtures thereof.18. The modified release formulation of claim 16 , wherein the hydrophobic polymer is selected from the group consisting of ethyl cellulose; methacrylic acid derivatives; cellulose acetate and its derivatives; poly vinyl alcohols and its derivatives; polyacrylamide derivatives; and mixtures thereof.19. The modified release formulation of claim 16 , wherein the wax is selected from the group consisting of glycerol palmitostearate; beeswax; glycowax; castor wax; carnauba wax; glycerol monostearate; stearyl alcohol; glycerol behenic acid ester; cetyl alcohol; natural and synthetic glycerides; waxes; fatty acids; hydrogenated ...

Подробнее
30-01-2020 дата публикации

METHODS AND COMPOSITIONS FOR DELIVERING MYCOPHENOLIC ACID ACTIVE AGENTS TO NON-HUMAN MAMMALS

Номер: US20200030285A1
Принадлежит:

The present disclosure provides methods and compositions for modified delivery of mycophenolic acid active agents, including sodium mycophenolate, in veterinary subjects. Presently disclosed methods and compositions are useful, for example, to treat autoimmune diseases, blood disorders associated with IMPDH activity, and immune rejection related to transplant or graft procedures. 2. A method for delivering a MPA active agent in a veterinary subject , comprising delivering , via oral administration , a MPA active agent to a lower gastrointestinal tract of the veterinary subject in a modified release such that following the administration , the veterinary subject has a plasma [MPA] Cthat is lower than a plasma [MPA] Cobtained from a reference veterinary subject administered a reference immediate-release MPA formulation.3. The method according to claim 2 , wherein the plasma [MPA] Cof the veterinary subject administration the MPA active agent in the modified release is less than about 90% claim 2 , less than about 80% claim 2 , less than about 70% claim 2 , less than about 60% claim 2 , less than about 50% claim 2 , or less than about 40% of the plasma [MPA] Cof the reference veterinary subject administered the immediate-release MPA formulation.4. The method according to or claim 2 , wherein the plasma [MPA] Cof the veterinary subject administration the MPA active agent in the modified release is less than about 80% of the plasma [MPA] Cof the reference veterinary subject administered the immediate-release MPA formulation.5. A method for delivering a MPA active agent in a veterinary subject claim 2 , comprising delivering claim 2 , via oral administration claim 2 , a MPA active agent to a lower gastrointestinal tract of the veterinary subject in a modified release such that following the administration claim 2 , the veterinary subject delivered the MPA active agent in the modified release has a Cplasma [MPA] of less than about 2500 ng/nL claim 2 , less than about 2000 ...

Подробнее
04-02-2021 дата публикации

GASTROINTESTINAL SITE-SPECIFIC ORAL VACCINATION FORMULATIONS ACTIVE ON THE ILEUM AND APPENDIX

Номер: US20210030669A1
Принадлежит:

The invention provides oral vaccine formulations which deliver an antigen in the vicinity of the distal ileum and the area of the ileal Brake and/or the appendix. These vaccines are useful in the treatment and/or prevention of variety of disorders, including viral and bacterial infections and cancers. Related methods of treatment which use the oral vaccine formulations of the invention are also provided. 1. An oral vaccine formulation which delivers an antigen in the vicinity of the distal ileum of the gastrointestinal tract and optionally , the appendix , the formulation comprising:(a) a plurality of cores, each of which comprise:(1) an antigen and an optional adjuvant;(2) a first enteric coating which encapsulates the antigen, which is substantially insoluble at a pH of less than a range of between about 7.0 to about 7.6, and which is comprised of one or more compositions selected from the group consisting of poly(dl-lactide-coglycolide, chitosan (Chi) stabilized with PVA (poly-vinylic alcohol), a lipid, an alginate, carboxymethylethylcellulose (CMEC), cellulose acetate trimellitiate (CAT), hydroxypropylmethyl cellulose phthalate (HPMCP), hydroxypropylmethyl cellulose, ethyl cellulose, color con, food glaze and mixtures of hydroxypropylmethyl cellulose and ethyl cellulose, polyvinyl acetate phthalate (PVAP), cellulose acetate phthalate (CAP), shellac, copolymers of methacrylic acid and ethyl acrylate, and copolymers of methacrylic acid and ethyl acrylate to which a monomer of methylacrylate has been added during polymerization; and optionally(3) a second enteric coating which is compositionally the same or different as the first coating, which is substantially insoluble at a pH of less than a range of between about 1.0 to about 5.3, which is encapsulated within the first coating, and which is comprised of one or more compositions selected from the group consisting of polyvinyl acetate phthalate (PVAP), cellulose acetate phthalate (CAP), shellac, copolymers of ...

Подробнее